Development and Evaluation of a Primary Care Drug Formulary by Hill-Smith, I.
"loot ti A- L, ev 
ff A 
Development and Evaluation of 
a Primary Care Drug Formulary 
MID Thesis 2000 
Ian Hill-Smith 
MEDICAL LIBRARY 
ROYAL FREE HO'vljPITAL 
HAMPSTEAD i 
ACCESSION 
\NUMBER 
Abstract 
Aim 
This study asks if practices can collaborate to create a shared formulary, 
which influences prescribing. 
Secondary questions 
If so, how long does the effect last? To what degree can such a formulary 
influence volume of prescribing, choice of treatment and cost? Is there a limit 
to the number of practices involved before the effect is lost? Are doctors more 
influenced by the formulary if they are closely involved with its creation? 
Method 
Controlled trial in two stages. 100 general practitioners from 20 urban and 
semi-rural practices and 50 community nurses worked with a small team of 
facilitators to create a formulary. Between 1991 and 1999, prescribing by the 
participating doctors was compared with the prescribing by all other general 
practitioners in the county. 
Results 
Collaborative work resulted in a countywide formulary for primary care. The 
use of information to support prescribing changed from a few practices using 
their own formularies, to an evidence-based formulary supported by all five 
Primary Care Groups in the county. Choice of treatment changed in seven out 
of thirteen therapeutic groups. Volume of prescribing reduced in three groups. 
Cost reduced by F-3000 per doctor per annum. 
Conclusions 
Sharing resources between practices to create a primary care formulary can 
lead to modest changes in prescribing, sustained over three years, and lower 
overall costs. The largest observed changes were a 14% change in the choice 
of drugs for musculoskeletal conditions, and a saving of E5000 per practice 
per year on antibiotics. Such changes, attributed to the development of a 
formulary, also occur in practices that have no direct involvement, but later by 
several years. The greatest change in prescribing is seen immediately after a 
formulary is created and in those involved with its development. The funding 
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for the work is estimated to amount to 17% of the saving on prescribing. 
Doctors and nurses from 32 practices can work together on such an 
intervention. 
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Introduction 
The Main Question 
Can practices collaborate to create a shared 
formulary that influences prescribing? 
This is the main question of this thesis. The hypothesis, that the statistical 
tests employed attempt to refute, is: Practices can collaborate to create a 
shared formulary that influences prescribing. 
Elements of this question are not original, but their combination and the scale 
on which the study has been conducted are. Formularies have been fairly 
extensively studied as one way to change prescribing. The question implies a 
formulary suitable for primary care but does not exclude recognition of local 
prescribing policies in secondary care. Collaboration is a key aspect. This is 
not a study into a practice-based formulary, but one founded on agreement 
between practices. What is being shared is the research ability needed to 
create such a formulary. Sharing too, in the decisions that need to be made 
and in the use of the final formulary. The process and the output must come 
from inter-practice co-operation, not from external directives or strong 
leadership within the group. Given this, will it be possible to create a 
successful formulary, one that is used and one that influences prescribing. 
Why it is important 
Historical perspective 
"It is an absolute obligation on doctors to use only drugs about which 
they have troubled to inform themselves. " 
William Withering 1785 
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After an unknown traveller had revealed the remarkable properties of a herbal 
tea containing foxglove leaves to William Withering, the use of the plant 
extract we now call digitalis rapidly became widespread. Many newcomers 
lacked Withering's skill in titrating the dose of this potent poison and as a 
result many patients died. Their physicians at the time blamed Withering for 
introducing such a substance, causing him to conclude 
".. shall we wonder then that patients refuse to repeat such a medicine, 
and that practitioners tremble to prescribe it"' 
One hundred and fifty years passed before the drug became accepted once 
again. Despite its long history, doctors could not agree about its use. 
I owe my reputation to the fact that I use digitalis in doses the text 
books say are dangerous and in cases that the text books say are 
unsuitable. " Karel Frederik WenckebacW 
In the times of these quotes, the problem was one of lack of knowledge; 
nowadays one of the main challenges facing primary care is how to navigate 
through the plethora of detailed information available to arrive at a point which 
is of benefit to a particular patient. 3; 4 Making information available may not be 
enough to make it useful. Independent practitioners will continue to echo the 
distrust of dictum expressed by Wenckebach. This is one aspect of why the 
question as to whether practices can share resources to create a joint policy is 
important. Subject matter too large for any one practice to tackle may either 
be taken on by a larger organisation, or examined by the co-operation of those 
practices that will be the users of the information. The two approaches can be 
combined to some extent, by a lead organisation involving end users in 
development. One example is PRODIGY. 5 Getting the balance right between 
central and local support for practitioners is critical for success. The 
background review in this thesis illustrates many attempts to improve 
prescribing which have depended for their success or failure on this balance. 
Students often prefer their own hand-written notes to textbooks. They may not 
be as complete or as accurate, but they are personal. The points that were 
important to the student are stressed, even if they seemed a minor detail to 
the lecturer or author. Medical education has evolved from passive attendance 
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at lectures and demonstrations, to early interaction between students and 
patients with real problems . 
6-81-ife long learning starts earlier and finishes 
much later than the 5 or 6 years spent at university? Personal learning plans 
are seen as key to continuing the professional development of doctors and 
nurses. Information sources need to fit into this educational environment if 
they are to be effective. 'O 
In 1990 the Department of Health recommended that formularies were locally 
developed and owned, preferably at practice level, and that participation and 
compliance with them should be entirely voluntary". Creating a local 
formulary provides a chance for participating doctors to update their 
knowledge on the pharmacology, use and acceptability to patients of 
commonly prescribed drugS12; 13 , and provides a starting point 
for later 
discussions of management policies 14 . 
Wide variations in prescribing 
There is wide variation in prescribing choices. '5 It has always been so, but 
from time to time it becomes the focus of attention, giving the press ample 
opportunity to offer the public an image of general practitioners prescribing 
haphazardly whatever medication happens to be in vogue. When the British 
National Formulary included a symbol to identify drugs'less suitable for 
prescribing'the headline from the Health Correspondent of the Guardian 
appeared as "E100m BILL FOR WRONG NHS DRUGS 06 It is not simply a 
matter of unnecessary expense. Professionals as well as the public find it 
difficult to understand why there can be so much variation between practices. 
There is a tendency to assume that all variation results from irrational 
prescribing, that a practice serving thousands of patients should on average 
prescribe much the same as any other practice of the same size. This would 
be an oversimplification of the reasons for variation. There may be good 
clinical reasons why one practice prescribes differently from another. Even 
within my own town, the practice running the student health centre would need 
to prescribe differently from the practice serving residents in local nursing 
homes, differently again from my own practice, which has twice the national 
average of pregnancies and children aged under five. Variation in prescdbing 
9 
0' 
between hospitals has been shown to reflect case-mix more than illogical 
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prescribing. Nevertheless, the degree of variation and the choice of some 
drugs known to be of doubtful value must represent areas where prescribing 
could be improved. 
The Prescription Pricing Authority provides feedback to all general 
practitioners on levels of prescribing and cost. Although this is useful (indeed 
this research thesis could hardly have been done without it), feedback based 
on overall levels of prescribing takes limited account of case-mix and therefore 
cannot reliably assess what really matters, which is whether prescribing is 
appropriate or not. I will return to this in the discussion section, but for now the 
point to note is that variation in prescribing is one indicator that the question 
as to whether prescribing can be influenced by an inter-practice formulary is 
important. 
The link between rational prescribing and lower costs 
In 1994 the Audit Commission reported that more rational prescribing by 
general practitioners would lead both to better quality care for patients and 
save E425 million a year"', but purely financial pressure to change prescribing, 
such as through incentive schemes, may prove to be a false economy if 
treatment is less effective19. 
Primary Care Groups and Trusts are obliged to have prescribing incentive 
schemes aimed at improving prescribing and reducing costs. Offering 
prescribers a financial incentive is just one of the ways to change prescribing. 
The section reviewing the various methods tried so far goes into this in more 
depth, but the relevance to the importance of my research question is that 
currently large funds are allocated to changing prescribing. Luton Primary 
Care Group has allocated just under E400,000 for the prescribing incentive 
scheme for the town this year. If better prescribing can result from helping 
practices to develop their own quality agenda, then money currently used for 
the incentive schemes nationally might be better used elsewhere. 
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Clinical governance 
While prescribing may be an unusual activity in that improvement in quality 
may be linked with reduction in cost, the main political and moral objective is 
to provide every patient with the treatment they need, when they need it, and 
to avoid harm caused by unnecessary prescribing. Whereas Prescribing 
Incentive Schemes are inherently financial, other methods of influencing 
prescribing may offer quality improvements first, with cost savings coming as 
a bonus. 
"The Government will require every NHS Trust to embrace the concept 
of 'clinical governance' so that quality is at the core. , 20 
The British Medical Association commented on the above by pointing out the 
moral dimension. 
"Clinical Governance will not introduce radically new or different 
proposals for doctors. Virtually every duty listed is already covered in 
the GMCs Duties of a Doctor. " 
Although Primary Care Groups were set up partly in response to the criticism 
that the NHS was providing 'care by postcode', this did not at first seem 
logical, given that they were local organisations. Locally created formularies 
could be seen as part of the problem, not the way forward. National bodies, 
such as the National Institute for Clinical Excellence would seem to be the 
way to ensure quality in prescribing amongst other treatments. However, later 
government papers gave insight into the balance of national and local clinical 
governance, which it described as: 
if. 
-a framework through which NHS organisations are accountable for 
continuously improving the quality of their services and safeguarding 
high standards of care by creating an envirom-nent in which excellence in 
clinical care will flourish.. 
t, 21 
11 
Far from replacing local initiatives, clinical governance was to depend on such 
activities to draw upon nationally available information in such a way that it 
could be integrated with clinical practice: 
"We need consistent action locally to ensure that national standards and 
guidance are reflected in the delivery of services. 
Creating a primary care formulary is one example of this, but does it achieve 
the aim of clinical governance? This question needs answering if we are to get 
the balance right between national, local and practice-based information. 22 . 
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Secondary Questions 
1. If the formulary does influence prescribing, how long does the effect last? 
2. To what degree can such a formulary influence the volume of prescribing, 
choice of treatment and cost? 
3. Is there a limit to the number of practices involved before the effect is lost? 
4. Are doctors more influenced by the formulary if they are closely involved 
with its creation? 
Each of these questions can be stated as hypotheses by setting limits to the 
degree of change that would be considered of interest and then attempting to 
refute each hypothesis using statistical methods. While this would be a valid 
approach it would be less useful than considering these question in a more 
qualitative way. For example, it would be helpful to know if a shift in the choice 
of drugs prescribed in a therapeutic group took effect immediately after a 
formulary event, and then decayed over a certain time. Whereas it would be 
less helpful to know the result of a test against a hypothesis that such a 
change in prescribing lasted for a particular and arbitrary length of time. 
These secondary questions are formulated to help future planning of formulary 
events, either in Bedfordshire or elsewhere. There can be no certainty that the 
answers obtained from the process adopted in Bedfordshire will apply 
elsewhere to a process that will have variations or major differences. In the 
discussion section I shall deal with this issue of how generalisable the findings 
are. If some degree of generalisable knowledge can be extracted from the 
results, then questions that face others in setting up a primary care formulary 
using shared resources might be easier to answer. Practical issues gave rise 
to the secondary questions listed above. Examples are: 
* Will review meetings be required to maintain an effect on prescribing? 
e If so, how often will they be needed? 
0 Is it reasonably likely that a formulary could improve care to a degree that 
could be assessed by firm end-points? 
How long after the formulary creation could such end-points be measured? 
Is it worth assessing volume of prescribing, or is a formulary only likely to 
change choice of treatment? 
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* How much time and money can be spent creating such a formulary without 
making a loss? 
* Would it be better to limit the creation of the formulary to one Primary Care 
Group / Trust area, or to share it across several? 
Is there an advantage in involving doctors in the process of creating the 
formulary? 
The last question in each of the above lists is restricted to doctors because so 
is the prescribing data in this study. It would be an assumption to extend any 
finding on this to the nurses who took part in the formulary creation and use. 
Limitations of the questions 
Certain aspects to these questions could be interpreted as very wide ranging, 
but all studies must limit the scope of their aim. My main boundary in this 
thesis is that I am not considering why doctors and nurses change their 
prescribing. This would be a major study in itself. All I have attempted to do is 
to test one method of creating a formulary to see if it does change prescribing. 
While feedback and comments from participants has helped to define the 
methods used to drive the process, this is not presented as data nor 
evaluated. It is included in sections on methods and discussion to illustrate 
how the process was fine-tuned to maximise its potential. 
A second limitation to the questions is included in the phrasing. The main 
question asks 'can practices collaborate.. ' Demonstrating one example of 
practices collaborating successfully would provide an answer: yes, it is 
possible. If the study were to show no effect on prescribing, then this would 
not discount the possibility, but simply fail to answer it. Quite a different 
question would be required to say whether any group of practices could 
collaborate to create an effective formulary. The difference is important. 
Showing that a particular group of practices can collaborate would suggest 
that running the process to create a formulary in a similar way could also be 
productive. Whereas different process, which selected practices instead of 
giving them the opportunity to volunteer, might or might not result in 
productive co-operation. This study cannot inform such a process. 
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Unlike randomised controlled trials in which questions or hypotheses are 
designed to maximize the general application of the results across all cases, 
this study on the creation of a formulary asks a more limited question. 
However, I believe the limited question to be more important. Adult education, 
including life-long learning for nurses and doctors, offers a wide range of 
different methods of learning and can be more effective if the method is 
matched to both the leamer's requirements and the subjeCt9; 23-26. Systematic 
practice-based interventions and outreach visits are seldom used by CME 
providers, but there is evidence that such methods are more effective 
educational tools than traditional lectureS27-30 . 
The formulary process made 
use of small group discussions and feedback to individuals and practices on 
their prescribing. Under these circumstances it is the limited question which is 
relevant. Asking a more general question might miss any effect that would 
naturally occur in a non-experimental setting with volunteer practices, and pre- 
selection of practices could, in theory, invalidate the findings on a random 
selection of practices, which would by chance be more diverse. 
There are limitations to the secondary questions too. If any effect lasts longer 
than the total duration of the study, nine years, then it will not be possible to 
say how much longer such an effect might last. Similarly a limitation to the 
number of practices involved can only be found if it is below the twenty taking 
part in this study at its close. Further information may be available later 
because the formulary is now countywide, but this would require collection of 
data comparing this county with another. 
The degree to which the formulary affects costs is limited to prescribing costs. 
So if a doctor opts for fewer prescriptions for non-steroidal anti-inflammatory 
drugs after discussing potential side-effects in one of the formulary meetings, 
and his volume of prescribing drops in comparison with control levels, then 
this will be shown as a saving in costs. What is hidden from this limited view is 
the possibility that the doctor opts for more referrals to a physiotherapist or 
osteopath. Overall costs to the health service or to the patient are not included 
in the question. Nor is the choice of treatment other than drug treatment. The 
only aspects that are included in the study are whether the formulary causes 
prescriptions to be written for different drugs or none at all. 
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Finally, the question whether close involvement with the formulary process is 
associated with a greater effect on prescribing is limited to asking if partners 
within a practice who attended meetings changed their prescribing more than 
partners who received copies of the formulary and gave consent for their 
prescribing to be monitored, but who did not attend meetings. Such a question 
is limited to doctors, not nurses for whom no prescribing data is yet available. 
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Background 
Reasons for attempting to influence prescilbing 
There is plenty of evidence for room for improvement in prescribing 
17-1 18; 31-35 
. 
g2l; 36-3 16,40- There are issues of quality in prescribin 9 and cost-effectiveness"' 
44. Much has been made of the wide variation in volume and cost of 
prescribing between practices from the prescribing data available to Health 
Authorities and Primary Care Groups and through national aud it18 . 
But many 
criticisms have failed to take adequate case-mix and other practice-specific 
factorS45-48, which have been estimated to account for 51 
%49 81 %50, oreven 
97%43 of the variation. Similar findings have been found in the secondary 
sector 
17 
. 
Now that Primary Care Groups (PCGs) have responsibility for clinical 
governance and prescribing budgets, interventions which are known to have 
51 
an influence are likely to be used within the geographical area of a PCG 
Methods of influencing prescribing 
Prescribing has been shown to respond to a variety of interventions, including 
the development of local formularies and contact with other health 
professionals, notably pharmacists. A formulary can be seen as occupying the 
middle ground between a set of guidelines in therapeutics and a limited list of 
recommended drugs aimed at reducing prescribing costs. If it can achieve 
both an improvement in quality and a reduction in prescribing costs, all to the 
good. However it is only one of many methods of influencing prescribing and 
the following sections put it into the perspective of what is known in more 
general terms about the options for education and guidance. 
This is the point at which to note that although it may seem inefficient for many 
different groups to be working on primary care formularies, education, 
discussion and contact with colleagues from other disciplines during the 
development of a formulary is an important and intrinsic part of the process, 
likely to play a major part in any effect of the formulary. The National Institute 
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for Clinical Excellence has recognized that for central guidance to be 
effectively implemented it will need the support of local initiatives. 
Before considering specific interventions that might influence prescribing, I 
would like to sketch the backdrop against which extra influences play. There 
are many continuing influences on doctors' prescribing decisions. The 
presence of these emphasises the need for baseline comparisons and control 
data when evaluating any method of changing prescribing. Natural fluctuations 
in the background influences can obscure, reverse or apparently enhance 
changes resulting from an intervention. I was therefore surprised to find a 
large number of uncontrolled, short-term before and after studies on 
prescribing interventions both in the literature and at a conference on this 
subject at the Royal Pharmaceutical Society of Great Britain. 
The backdrop of continuing influences is summarised in the Tables 1-3, 
which are based on a focus group discussion of GPs, researchers and health 
economists held at the Department of Health on June 8 2000.1 have omitted 
some of the outdated or particularly minor influences, and attempted to rank 
the influences roughly into the order of relative importance. Some tables I 
have combined to give an impression of where national and local work 
corresponds. Some items appear in more than one table, and even those that 
are listed just once have some influences in other areas. 
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Guidance 
National Local 
Formularies District, Primary Care 
British National Formulary 
Group / Trust, Practice, Hospital 
National prescribing centre and MRec 
bulletins* e 
Drug and Therapeutics Bulletin e 
Primary Care Group / Trust 
Prescription Pricing Authority Bulletins Pharmaceutical Advisor - Newsletter, 
and data e contacts, prescribing feedback, 
practice budget 
National Institute for Clinical 
Health Authority / Regional 
Excellence Guidelines and product Prescribing advice 
appraisals e 
Scotland SIGN - used in England 
Drug Evaluation Committees* Joint sector prescribing committee 
International and national guidelines e Local disease / referral guidelines e 
Committee on Safety of Medicines Independent pharmaceutical advisors 
Bulletins 
PRODIGy* e 
National Performance Framework e 
Nation Service Framework e 
Public Health / Immunisation targets Health Improvement Programme e 
*- Now closely linked to National Institute for Clinical Excellence 
e= also available in electronic form 
Table 1. Sources of guidance on prescribing 
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Drug Information 
Independent Industiry dependent 
British National Formulary e Monthly Index of Medical Specialities e 
Independent research in peer- 
reviewed journals ' 
Data on file 
Cochrane Database e Data sheet compendium e 
Bandolier e Trade press and Advertising 
Drug and Therapeutic Bulletins e 
Primary Care Group Pharmaceutical 
Advisors 
Company representatives 
Prescribing data (PACT) 
National prescribing centre and MRec 
bulletins* e 
Continuing Medical Education Sponsored Medical Education 
Drug Information Bureau Company information centre 
Textbooks 
Courses on pharmacology 
Clinical Audit Projects / MIQUEST Sponsored audit 
*= Now closely linked to National Institute for Clinical Excellence 
e= also available in electronic form 
Table 2. Sources of information on drugs 
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Drivers external to the practice 
Clinical Quality Drivers Incentives 
Primary Care Group: Peer pressures, Prescribing Incentive Scheme Generic 
prescribing monitoring, prescdbing targets 
pharmaceutical advisor contacts, Repeat prescribing protocols 
Health Improvement Programme Doctor awareness of pdces 
Clinical Governance 'Quality is Less risk of litigation and 'defensive 
statutoryl. medicine' 
National Institute for Clinical 
Excellence 
Evidence-based healthcare Practice prescribing budget 
Profits from vaccine purchase, Red book rules 
administered drugs and dispensing 
National Service Framework 
Commission for Health Improvement Revalidation 
Clinical Audit Programme Prescribing data feedback 
Media and better informed, more 
National Patient and User Survey demanding patients 
University Education Postgraduate qualifications 
Table 3. Sources of influence on prescribing external to practices 
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Systematic Review 
The next section includes a systematic review of trials on interventions aimed 
at changing prescribing in primary care. Criteria for inclusion in the review 
were as follows: 
0 influence on primary care prescribing - direct or indirect 
intervention targeted at prescriber - doctor or nurse - direct or indirect 
9 type of intervention as described by Gill et a152 
"That is distribution of educational materials; conferences or educational meetings; 
interventions that involve locally deriving consensus recommendations; educational 
outreach visits that take place in the participants' location; the influence of local 
opinion leaders (educational influentials); patient mediated interventions in which 
information given to or received from patients is intended to influence professional 
practice; audit and feedback where physicians receive summary information on their 
practice over time; reminder systems where physicians receive specific reminders at 
the time of intervention to enhance particular strategy or behaviour; marketing, in 
which physicians are targeted by interventions similar to those used to market 
commercially specific desired practices. it 52 
Although Gill cited criteria from a review in the Cochrane Library, which has 
since been updated 53 , the criteria 
I have used are based on the above criteria 
plus interventions where no written education materials were mentioned. 
Non-randomised studies on doctor behaviour 
I chose not to specify a study design criterion. Most systematic reviews look at 
randomised controlled trials. The great advantage of this design is that the 
results are more easily applied in general. Non-randomised studies may show 
an effect which only applies under the particular circumstances of the study. 
Despite this, to exclude non-randomised studies misses important information. 
Prescribing behaviour will inevitably depend on the characteristics of the 
person prescribing. Randomisation of people into a trial will misalign some 
22 
people into groups in which their preferred behaviour will be thwarted, for 
example an enthusiast for pharmacology audit being allocated to a control 
group receiving no support for changing prescribing, and vice versa. If 
randomised controlled trials show no cost-effective outcome from educational 
intervention 53 
, the natural conclusion would be to avoid wasting time on such 
interventions on a wider scale. However, such interventions could be effective 
when applied in a non-random way, and in practice this is what happens. The 
recipient largely determines choice of continuing education. If only those who 
choose to take part change their prescribing as a result, then the information 
gained from randomised studies is misleading. 
There is a need to balance the interests of research, development and 
practice 54 . The development of the formulary in Bedfordshire provided the 
ground for a 'natural' experiment to test the effect of collaboration and sharing 
of resources. Randomising practices to participate or not would have excluded 
some interested practices from a major educational event. Practices selected 
as participants, but less interested in developing a formulary, might have had 
problems collaborating with others. 
Search Strategy 
A variety of search strategies were used. Electronic searches were most 
useful for recent literature. Reviews and meta-analyses were targeted first and 
those found provided many more references to original research. A broad 
search was used to capture a variety of interventions aimed at influencing 
prescribing, not just formulary development. Articles on both primary and 
secondary care were accepted initially. Some centred on secondary care had 
influences on p6mary care prescribing, but those of little relevance to primary 
care were excluded from further review. The specific strategies, given in Table 
4, aimed at finding articles that evaluated an intervention in terms of 
prescribing either numerically - number of items, cost, degree of acceptance 
of guidelines or formulary - or qualitatively, based on opinions, acceptability, 
impact on clinical freedom, and perceived usefulness. The quantitative 
research papers had a more direct influence on the evaluation methods 
adopted for the Bedfordshire formulary. The qualitative papers were relevant 
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to the methods we used for the intervention. Only minor details of how the 
Bedfordshire formulary is developing have changed in the past nine years. 
The core activities of providing and a forum for discussion, literature research 
and feedback on prescribing for the development group, have been constant. 
LE/Emictronic sources 
The electronic searches were done using 
Medline 1966 - 2000 
EMBASE 1988 - 2000 
Cochrane Library 2000 Issue 2 from 1966 
British Medical Association library database from 1966 
Human sources 
Further assistance was forthcoming from librarians at Luton & Dunstable 
Hospital and the British Medical Association. People working in the field and 
supervisors of the work on this thesis, suggested other articles. Older 
references, unpublished work and obscure publications were obtained from 
personal contact with academic departments of general practice, the national 
prescribing centre, personal contacts at national conferences, focus groups 
and reviewers of papers submitted as part of the formulary work. 
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The P, hand column in Table 4 is the number of useful references obtained 
after assessing all 401 found by the strategy. 
Search Strategy Number Meeting 
Review Criteria 
1 journal of medical education 15 
AND prescriptions, drug 
2 prescriptions, drug (exploded) 18 
limited to review 
3 BMA standard search for all reviews, meta- 24 
analyses and systematic reviews 
AND prescriptions, drug 
4 BMA standard search for Randomised 32 
Controlled trials 
AND prescriptions, drug 
5 education, medical, continuing 42 
AND prescriptions, drug 
Table 4. Search strategy for the systematic review 
Review 
The review reference list includes those studies that support the background 
to this thesis and meet the criteria given above. The scoring system in Table 5 
is based on that proposed by Johnson et a155. I added two extra parameters: S 
for sample size and D for duration as these are features which affect the 
power of studies on interventions to affect prescribing. An original parameter 
for follow-up rate was removed as it would be inappropriate in this context. 
The zero score for unit of sample was originally 'patient or family'. This was 
changed to'unspecified. Maximum score is 12. 
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Symbol Parameter Scoring criteria 
S Sample size 0= one unit 
1=2-5 units 
2= >5 units 
U Unit of sample 0= unspecified 
1= doctor or nurse 
2= practice, clinic, district 
R Randomisation 0= selected / concurrent / historical 
1= quasi-random 
2= randomised 
B Baseline 0= no statement 
1= differences unadjusted 
2= none I adjusted 
0 Outcome 0= no explicit criteria 
1= subjective / not blind 
2= objective / blind 
D Duration 0= <1 year 
1=1-2 years 
2= >2 years 
Table 5. Scoring of papers in the systematic review 
The first two parameters give a weight to the size of the sample studied. At 
least 6 practices would need to be included for a study to score the maximum 
of 4 on these two parameters. Randomisation increases the general 
applicability of the results and is scored 2 for formal randomisation, 1 for 
methods which include some degree of randomisation. All non-randomised 
studies score zero. Baseline scores reflect whether the effect studied is 
compared with non-intervention activity, either on a historical basis or a 
simultaneous comparator. Outcome in the case of educational interventions 
was not studied blind, so the score for this parameter depended on whether 
the outcome had been clearly defined, such as a change in the choice of 
drugs prescribed or the cost of medication. Duration is important in this field 
because of the effect of season variation in prescribing and the chance that an 
intervention may give rise to immediate but short-lived effects. Studies under 
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one year in length could not adequately take account of these difficulties and 
score zero. 
The results of the review are in the Review References section, near the end 
of the thesis, just before the Main References section. 
What is known from previous research 
Education 
Randomised studies have not shown a clear effect of written material in 
influencing prescribing52-153. Strategies that rely primarily on dissemination of 
advice, particularly if unsolicited, show no effeCt56-59 . 
There are exceptions to 
this when information concerns a narrow range of drugs with a particular 
prescribing problem, such as over-prescribing of antibiotics 60-62 , under- 
prescribing of antidepressantS63 or tranexamic acid 64, or a particular problem 
in the public intereSt60; 65 . 
There are studies that show no effect of newsletters 
even under these circumstances66. 
Curiously the same intervention of an educational bulletin on the same group 
of GPs influenced knowledge and intentions to prescribe for renal colic but not 
irritable bowel syndrome 67 . 
This may have been because the content of the 
advice on renal colic was perceived as being more evidence-based. Targeted 
guidance, such as writing to the doctors of patients receiving drugs less 
suitable for prescribing, can reduce inappropriate prescribing68. 
Formularies are educational if the prescribers are involved in development or 
maintenance. Under these circumstances prescribing changes in 
participantS69-73. The studies on formularies developed in this way find a shift 
toward prescribing drugs within the formulary and a reduction in drug costs. 
Sometimes this was an inevitable finding because the formulary was based on 
existing prescribing of a practice or small group, reinforcing behaviour rather 
than presenting any challenge to reconsider the evidence and change4 
71. 
Recommendations to start creating a formulary in this way76; 
77 are misguided. 
Evidence for formularies influencing prescribing when the users are not the 
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developers is much less strong. The adherence to a formulary will depend on 
the area of coverage. A narrow formulary of first line drugs will show much 
lower levels of adherence than a broader formulary offering more choiceS78. 
Special function formularies, such as for emergency drugs or out-of-hours 
cover, may show high levels of adherence if the demand for alternative 
treatment is low, or low levels of adherence if the formulary is bypassed by 
alternative sources of drugs, such as samples supplied to deputising services. 
Visits by pharmacists and clinical pharmacologists to provide general advice 
and education are not effective 
79 
unless linked to prescribing feedback 
80 
, or a 
specific problem, such as dose adjustment of allopurinol8', or the overuse of 
antibiotics for viral illnesseS36; 
82, 
or use of drugs less suitable for prescribing5"; 
83; 84 
. 
The strongest effects have been detected when a colleague from the 
same profession ViSitS66; 
85. 
Small group discussions and 1- or 2-day workshops are effective 
86-89 
, in 
contrast to didactic style9o, or conventional lecture type education. This may 
depend on cultural background and what is expected of education9'. 
Involvement of prescribers can be done through mailed questionnaires and 
nowadays via the Internet. This is more likely to achieve a change than simple 
distribution of advice, particularly in younger G pS92 . 
This is necessary 
because doctors are slow at implementing change following publication of 
evidence based research 93 . 
The use of prophylactic aspirin is unquestionably 
valuable, and yet in 2000 only 78% of patients in Luton who should be taking 
aspirin are doing S094. Similarly the use of beta-adrenoceptor blocking drugs 
after myocardial infarction has been 20 years in gaining acceptance despite 
good clinical trials. 
Continuing education is influential if sufficiently structured 
82; 95 
. 
Doctors will 
usually choose this education for themselveS96, so this may miss those less 
interested in prescribing matters who have most to gain. 
Publicity campaigns may be more effective if aimed at both professionals and 
the public simultaneously, thereby increasing demand and perceived demand 
97 
at the time information is provided to support prescribing 
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Health Authorities can utilise the work of pharmaceutical company 
representatives, but no changes in prescribing resu It98. 
Feedback 
Feedback influences prescribing if it is specific to a prescriber99, especially if it 
identifies a specific problem of that individual's prescribing87; 100, or if presented 
by a pharmacist persona JJY101-103 . 
The effect is lost after 2 years when doctors 
have become tolerant to receiving feedback in the same format'". 
Critical events provide an opportunity for education through review. This is 
practical only within a culture of shared information on prescribing, where it 
can achieve a change in about half the doctors who declare they intend to 
05 
change prescribing as a result of feedback about a particular event' . 
Shared 
prescribing data within Primary Care Groups may make this easier in Britain, 
but the public image of a profession organising education on the basis of 
failures may not be easy to sustain. A more proactive approach would need to 
be used in parallel. 
Suggesting simple generic substitution to reduce costs has been effective, 
106 
more complex unsolicited advice is ignored 
The evidence for feedback on prescribing producing change in subsequent 
prescribing towards higher quality indicates that there is willingness on behalf 
of professionals to improve given a guide as to where to make the 
improvements' 07 . 
This is important for the future of financial incentive 
schemes, which risk undermining the professional ethos of continuing 
professional development to achieve high quality care for non-financial 
rewards. The cost of the schemes to the Health Service may be seen as a 
poor way to use money, even by the people who receive it. Some GPs 
expressed this view at the Department of Health focus group on 8 June 2000. 
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Prescribing support 
Providing information intended for use at the time of prescribing is a method 
dependent on reference material rather than education which aims to prepare 
a prescriber with knowledge to make informed decisions. Until recently, such 
reference material has been printed, but increasingly it is becoming available 
electronica Ily5; 108-112 . 
This brings the usual advantages of fast searching 
through electronic forms of indexes and scanning software, instant updating, 
together with the important advantage that prescribers can access information 
'just-in-time'. Information can be presented automatically by cross-referencing 
to diagnostic or prescribing data at the time of entry on to a clinical computer 
system. Simulated cases have shown such methods to affect prescribing 
decisions' 13 
. 
The use of a computer to prescribe is associated with lower 
CoStS1 14. 
Financial 
Every Primary Care Group / Trust is required to support a prescribing 
incentive scheme. Thus the prevalence of such schemes is not evidence for 
their effectiveness, as is sometimes stated. 
Financial savings as a result of lower prescribing costs can accrue to the 
practice. Formularies have achieved this in the past both before 
12; 11' and after 
the introduction of fundholding 41. Stepped formularies where cheaper drugs 
are tried first before more expensive drugs may be effective in reducing costs; 
even when there is no effect on the volume of prescribing44. In general, those 
formularies which influence prescribing choices will reduce 
Costs t0069; 
70. 
Knowledge of costs influences prescribing decisions"6. GPs are becoming 
more aware of the cost of drugs and this is playing an increasing part in 
prescribing decisions. 
The way in which doctors are paid alters the likelihood that an intervention will 
change prescribing. A variety of methods, which have been successful 
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elsewhere, failed to change prescribing within a prepaid group practice in 
Canada' 17 
. Private primary care doctors in the United States were unaffected 
by an educational feedback intervention that did change the prescribing of the 
health maintenance organisation in the same area 
118 
. 
Health 
There are relatively few studies assessing the health of patients following an 
intervention to improve prescribing. Mostly surrogate measures have been 
used as endpoints, but May et al showed both a 28% reduction in the 
prescribing of non-steroidal anti-inflammatory drugs and a 70% reduction in 
the rate of admission for drug associated gastro-intestinal disorders"9. 
Regulation 
Statutory regulation can have a large and rapid effect on prescribing, for 
example the introduction of the'black list'of drugs not available from the NHS- 
Less formal advice can have a major impact. Recent examples include central 
advice on treatment for sexual dysfunction in men and prescribing for 
influenza. The National Institute for Clinical Excellence has a major role in 
future recommendations, but controversies over the legal and political issues 
of market regulation may be a stumbling block. The Prescription Price 
Regulation Scheme was renegotiated in 1999 with a reduction in the cost of 
branded medicines of just over 4%, but the pharmaceutical industry were free 
to adjust relative prices of drugs. This resulted in some odd pricing structures; 
for example only one dose of the metered dose inhaler of Flixotide was 
reduced while the other retained at a premium price. The sudden increase in 
cost of generic products swallowed up funds intended for modernisation of the 
health service. These swings will influence prescribing choices. Interventions 
aimed at reducing costs will need to take account of such changes. If prices 
fluctuate on a shorter time-scale than most interventions, then 
recommendations based on value for money become unsustainable. Over the 
next four years until the next regulation scheme review, the Department of 
Health is considering the assertion coming from industry that competition and 
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a free-market are now sufficient to control the NHS drug bill, as it does in 
some other European countries. 
Review summary 
Table 6 summarises the findings from the systematic review. Various methods 
of influencing prescribing are listed in the left hand column. In the middle 
column are the review scores of the papers supporting the method having an 
influence on prescribing. In the right hand column are the review scores of the 
papers showing no effect. The order of the rows starts with the method with 
the most evidence for influencing prescribing at the top, going down to the 
least at the bottom. The order is only a guide based on the score totals. Some 
methods have scores in both columns, which reflects the method being 
effective only under certain circumstances, or inconclusive evidence as to 
whether there is any influence on prescribing or not. 
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Score 
Method 
Influence No influence 
Formulary development by prescriber 106_ý, 9", 8 
70 
, 
7 74 ,7 
73 61 15 5 41 
4 78 75 ,3 
Continuing professional education 1191,11100,1 o96, 
1063 8 65 8 61 4 120 
Feedback on prescribing 121 
04,11118,1 dl'-' 11118,1o59 
W03 lo82 9101, 
, , 
968,962 
Drug educator visit to prescriber 1183, 
W4, W19, 979 
8 66 8 85 
Pharmacist visit to prescriber 
--f-17 lo36,980, 11117,979 
9101,7 81 14 
84 
_ _ Computer support ,8 
44 71 14 _611 ý 
Individualised teaching using critical 
9105 
events 
- - 
Therapeutics discussion group 
71 %9 8 10 5 
- Information campaign 0,5 
97 1019 
Problem-based learning 1095 5 
92 
Providing doctors with information on 71 
16 71 06 
drug costs 
Doctor - patient discussion group 
1o89 
Doctor visit to prescriber 
Media attention (slow change) 7 
93 
Pharmacist review of medication 51 
02 
Health Authority - Industry partnership 
lo98 
Drug bulletin 11118,1 
o67, qbb, 1-8,1190,1067, 
7 93 957 8 
66 
Table 6. Summary of findings of the systematic review 
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Method 
Developing the formulary 
Participants 
South Bedfordshire GPs 
The first cohort of participating practices was invited. At least one partner from 
each practice was a member of the South Bedfordshire Practitioners' Group, a 
collaboration of GPs with a ten year history of research, developing out of a 
young practitioners' group originally set up to offer mutual support. 
Out of 300 general practitioners in Bedfordshire, 50 participated and the 
remaining 250 formed the control group. The participating doctors were from 
11 urban and semi-rural practices. Twenty-seven general practitioners 
attended at least one of the formulary meetings and every practice had at 
least one participating partner. Everyone received copies of the formulary. All 
practices agreed to participate, to help create the formulary, and all but one 
partner gave signed consent to allow analysis of prescribing data. The 
practice with a dissenting partner could not be included in the analysis. Two 
practices dispensed a minority of their prescriptions. 
North Bedfordshire GPs 
The second cohort, from a different area of the county, had no formal contact 
with the development that had been occurring in the South. By 1995 the 
formulary in the South had been established, but it had been achieved by a 
group of practices that were accustomed to collaborative work. Could the 
same be achieved in a different part of the county where no such prior group 
co-operation existed? To find out, an initial presentation at the postgraduate 
institute in Bedford launched an invitation to practices in the area. Nine 
responded as being willing to participate in developing a primary care 
formulary along the lines of the South, 
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Whereas the South's formulary had used 3 previously published formularies to 
seed the shortlist of drugs to be considered, the most up-to-date formulary 
was now the South Bedfordshire Primary Care Formulary, which was adopted 
as the shortlist source. In all other respects the process was the same for both 
cohorts. 
Nurses 
Nurses started coming to the formulary meetings in 1996, when wound care 
items were included. Over the following four years a total of 50 nurses 
attended at least one meeting. They were either district nurses or practice 
nurses. Most worked with one of the subject practices. As the wound care 
section enlarged and became more widely known in the nursing community, 
nurses from non-participating practices joined. By February 2000 nurses had 
attended from 12 practices not in the above cohorts. Thus in total 32 practices 
have contributed to the formulary to date. 
Timing 
Formularies were distributed to all participants and their partners automatically 
on New Year's Day for each year. In the initial years for each cohort, when 
only part of the range of therapeutic groups had been considered, partial 
formularies were distributed. Prescribing data for the therapeutic groups 
covered was collected for analysis with the exception of wound care products, 
which were a later addition to the formulary. The first quarter of every year 
was used throughout to avoid seasonal variations. The first data set January - 
March 1991 was prior to any development work on the formulary. 
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Timing 
Year 
- 
South Cohort 
- 
North Cohort 
lV9 1 Baseline prescribing data obtained. 
Development of formulary for 
therapeutic groups: 
2 Cardiovascular 
3 Respiratory 
10 Musculoskeletal 
1992 1 Gastrointestinal 
4 Nervous 
5 Infections 
6 Endocrine 
7 Obs & Gynae 
8 Nutrition & Blood 
1993 11 Eye 
12 ENT 
13 Skin 
15 Anaesthesia 
Development of South formulary 
complete. 
1994 Update 
1995 
1996 A8 Wound Care Baseline prescribing data obtained. 
Publication of results Development of formulary for 
therapeutic groups: 
1 Gastrointestinal 
2 Cardiovascular 
Update - drugs 3 Respiratory 10 Musculoskeletal 
1997 4 Nervous 
5 Infections 
6 Endocrine 
7 Obs & Gynae 
8 Nutrition & Blood 
11 Eye 
12 ENT 
13 Skin 
15 Anaesthesia 
A8 Wound Care 
Development of North formulary 
complete. 
1998 Prescribing data collected to assess 
effect on North cohort. 
Process to combine formularies 
1999 New formats developed 
2000 Update - drugs 
Process to combine Wound Care section with county education programme 
Update - Wound care 
Table 7. Formulary development 1991 - 2000 
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Aim of formulary 
The aim was to include drugs that would be first-line treatment for 80% of all 
conditions seen in primary care. So if a doctor entirely agreed with the 
formulary, 80% of the prescriptions that doctor issued would be for drugs in 
the formulary. Such an aim is arbitrary, but necessary to define the intended 
scope of the formulary. The structure of the formulary was to be a list of drugs 
indexed according to the classification used by the British National Formulary, 
with notes explaining the reasons for the selection. Page numbers were 
avoided to allow for easy replacement of updated pages. The latest version of 
the formulary is on the CDROM included as part of this thesis. Instructions for 
use are in Appendix A. 
Preparation prior to meeting 
Drugs in any of three published primary care formularies'13,14,15 seeded a 
short-list for inclusion in the new formulary. A single sheet summarising 
information on each drug was sent to every participant prior to each meeting. 
Information was drawn from the British National Formulary, the drug data 
sheet, primary care and local hospital formularies. Participants reviewed this 
information before sending proposals for additional drugs or recommendations 
to exclude drugs on the short-list. Reasons were invited on single page, 
structured questionnaires, which were sent to the pharmacist, who then 
researched the corresponding evidence. The forms are in Appendix B, with 
electronic versions forming part of the formulary on the enclosed CDROM and 
recommendations can be made online at www. wlhc. demon. co. uk. This system 
targeted the time of the pharmacist to searching for the information relevant to 
the issues that would be raised by the participants at the meeting. At the 
meeting, the literature research findings were discussed, and a vote was 
taken on each proposal. A drug was included in the formulary if it achieved a 
simple majority. 
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Schedule of events 
The timing of events needed to take account of the following: 
M doctors and nurses needed to be introduced to a vision of the final primary 
care formulary so they could make appropriate proposals 
m they also needed to decide on the process by which such a formulary 
could be achieved at the outset 
m new participants would join the group who would need to be aware of the 
above, so the information had to be re-iterated or made apparent through 
clear correspondence allowing sufficient time for them to catch up 
0 proposals and exclusions had to be received by the pharmacists 
sufficiently in advance of each meeting to allow time to research the 
evidence 
M meetings had to be held at a time and place convenient to doctors and 
nurses who were likely to have a full clinical commitment 
M the amount of time available to the participants limited the coverage of any 
one meeting to discussion of a single major therapeutic group such as 
cardiovascular drugs or wound care 
smaller chapters of the British National Formulary, for example those 
dealing with conditions of the ear and eye, could be covered in one 
meeting 
to allow comparison of prescribing influences with minimal influence of 
seasonal variations in disease, formularies had to be distributed at the 
same time of year 
any possible advantages of the formulary would be delivered earlier if 
therapeutic groups more likely to permit a change in prescribing, such as 
those covering medication for common, acute, short-term conditions, were 
tackled first, and this could also encourage interest 
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Table 8 shows the initial schedule for events in the South of the county. 
18 September 1991 Introductory Meeting 
3 October 1991 Deadline for receiving proposal and exclusion forms 
17 October 1991 Musculoskeletal drug meeting 
8pm Wigmore Lane Health Centre 
5 November 1991 Deadline for receiving proposal and exclusion forms 
19 November 1991 Cardiovascular drug meeting 
8pm Wigmore Lane Health Centre 
4 December 1991 Deadline for receiving proposal and exclusion forms 
18 December 1991 Respiratory drug meeting 
8pm Wigmore Lane Health Centre 
1 January 1992 Formulary distribution 
January 1992 Amendments meeting 
June 1992 Results feedback meeting 
Table 8. Timetable for the South Bedfordshire cohort. 
From this initial timetable we learned what worked well and what could be 
improved for future arrangements. 
Where the timetable failed 
The most important lesson was that the single pharmacist found it difficult to 
undertake the necessary information research in the two-week gap between 
receiving the suggestions from doctors and the meetings to discuss the drugs 
and the information in question. This was despite the pharmacist having been 
seconded to the work on the formulary twenty hours per week, including 
weeks before the deadline for proposals and exclusion, and the fact that she 
is a highly experienced senior pharmacist operating with all the resources of a 
drug information bureau. It was a demonstration of how difficult it would be for 
any one practice to undertake such work itself or bear the cost of employing 
such professional help. For the next batch of therapeutic groups considered 
in 
the following autumn in 1992, the deadline was moved to 1 month before the 
discussion meeting. This had an apparent advantage that proposal and 
exclusion forms could be delivered by hand at one meeting for drugs to be 
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discussed in the next. In fact, this confused some participants and I would not 
recommend it. It was difficult to spend time considering suggestions for drugs 
in one therapeutic category, fill out the forms, then attend a meeting that 
discussed a different therapeutic group. The small saving in postage for the 
participants was not worthwhile. 
Since 1992, the time allowed for researching the information has lengthened 
further: participants are now required to submit proposals and exclusions a full 
two months ahead of the meeting in September 2000. This is despite the fact 
there are now five full-time primary care group pharmacists dividing the 
proposals and researching one fifth of them each. In addition, three other 
pharmacists are available for backup: Janet Clarbour the original pharmacist 
who still runs the hospital-based drug information bureau, Karen Homan and 
Jacqueline Clayton, pharmaceutical advisors to the Health Authority. 
Furthermore access to information has become dramatically easier over the 
past nine years. I suspect it is this that has enabled more information to be 
available for assessment and therefore increased the time taken to research 
the questions raised by the proposals. Perhaps there has also been an 
increase resulting from a cultural shift demanding more detailed and 
formalised appraisal of evidence. 
The idea behind the amendments meeting was to ensure that the formulary 
had correctly reported the outcome of discussion (similar to ratifying the 
minutes of a meeting), but as there were no amendments required by the 
participants, the meeting was cancelled. 
June was Optimistic for a feedback meeting. Prescribing data for the first 
quarter of 1992 was not received until mid May. The requirements of the 
Prescription Pricing Authority regarding confidentiality meant that all the data 
were printed and delivered in boxes by post. They had to be transferred to 
computer before any analysis could be done. Even with only three therapeutic 
groups, it was a tight schedule to provide every participant with feedback on 
their individual and practice prescribing by October, which is when the first 
feedback meeting actually took place. Electronic formats of data now available 
would certainly speed up this process, but pre-designed analysis methods 
cannot be employed to assess the impact of any one particular formulary, so 
such targeted analysis is still time-consuming. 
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Where the timetable succeeded 
The meetings were well attended. Twenty-six general practitioners from the 
South of the county attended the first meeting. It would be expected that 
numbers would fall with time, but this did not happen. Fifty-six professionals 
including general practitioners, nurses and pharmacists and two 
pharmaceutical advisors from another county attended the latest meeting on 
17 February 2000.1 have no evidence as to why the meetings have sustained 
popularity, but aspects that I believe have helped include 
0 the right time - 8prn - allows general practitioners to reach the meeting 
after surgery 
" the right day - never a Monday or Friday 
" good food provided from 7.30pm because participants will not have had 
time to eat after clinical commitments 
" finish by 1 Opm usually, or at the very latest 10.30pm 
" choice of venue size according to the size of group, more intimate rooms 
for smaller groups, lecture hall size for large groups 
choice of venue local to participants - now that the formulary is county- 
wide the venue is in the centre of the county 
When the formulary meetings were moved to the North of the county, the 
lessons learned in the South were taken into account and the successes were 
kept. So the timetable copied that which had developed in the South, with 
local evening meetings and a four-week slot for research to be undertaken 
after the receipt of proposals and exclusion. 
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Who attended the meetings 
Meetings were attended by general practitioners and community-based 
nurses including practice nurses, district nurses and specialists in wound care. 
Pharmacists presented evidence. Initially this work was undertaken by the 
local hospital formulary pharmacist, who was employed half time, with money 
from the project grants, to support the primary care formulary development. 
This had several bonuses: 
experience of formulary evidence research 
detailed knowledge of the local hospital formulary 
0 resources of a drug information bureau 
As the formulary has become county-wide and with the emergence of primary 
care groups, the work of researching the data for the meetings and presenting 
the evidence to the participants has been taken over by the primary care 
group pharmaceutical advisors. Further pharmacy support is provided by an 
ongoing link with the hospital pharmacists and the Health Authority 
pharmaceutical advisors. 
A consultant in Gerontology with a special interest in clinical pharmacology 
provided Independent advice on the use of drugs. Modest honoraria were 
originally funded from the project grants, but more recently this has been 
funded directly by the primary care groups. There was a specific request from 
the participating GlPs to continue to support the input from this member of the 
support team. Advice on clinical pharmacology is seen as particularly useful 
by the generalist clinicians attending the meetings. This may be because it is 
free of speciality bias. 
Particular therapeutic groups of drugs required input from other support 
personnel. Consultant microbiologists from both hospitals in the county 
attended the meeting on antibiotics. Their knowledge of local sensitivities was 
seen as crucial to the selection process. The general practitioner adviser 
to 
the Royal College of Obstetricians and Gynaecologists attended the meeting 
that included contraceptives. 
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Two nurse specialists on wound care, one from the North and one from the 
South of the county supported the meetings on wound care products in their 
respective localities. This year, the educational course on wound care has 
been integrated with the formulary with assistance from the nurse tutors. 
Structure of the meetings 
Meetings started at 8pm after half an hour for food. The aim was to finish by 
1 Opm, but approximately one third of the meetings continued up to half an 
hour longer. All meetings were approved for two hours of post-graduate 
education allowance. One main therapeutic group of drugs, using the British 
National Formulary classification, was discussed at each meeting. Towards 
the completion of the formulary smaller therapeutic groups were combined, 
such as drugs acting on the eye and ear. 
Initial meetings needed time to discuss the aim of the formulary process and 
the way in which the discussions could be structured, but as participants 
became familiar with the process and fewer people were attending for the first 
time, this became unnecessary. 
This was followed by a presentation on one therapeutic subgroup of drugs by 
the pharmacist. The number included in the presentation before discussion 
depended on the nature of the drugs. The aim was to include all the 
information found by the pharmacist that was relevant to an informed choice of 
drug(s) within the therapeutic subgroup. Usually this would be 3-5 drugs, but 
sometimes 2 or up to 10 for groups of emollients or contraceptive drugs. 
Overhead projection was used to show the data. A photocopy provided for the 
chairman helped form the notes to the formulary. 
Each presentation was followed by open discussion amongst the GPs and 
nurses. The content fell into these forms: 
reflection of experience in the light of the evidence 
opinion in support of or in contrast to evidence 
extra information not discovered by the pharmacist, including unpublished 
observations 
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M review of the evidence from the patient's point of view; issues of 
acceptability 
review of the evidence from the practice point of view; practical issues of 
prescribing interacting with general problem management 
The pharmacist's role was to find evidence to help prescribers make an 
informed decision about inclusion of a drug or product in the formulary, with 
sufficient comparative data to support the corresponding notes. This required 
a variety of sources. The drug information bureau provided the infrastructure 
for access to published material in journals, conference abstracts, books, 
datasheets, case studies, bulletins and correspondence with drug evaluation 
committees both local and national. In addition, the contact with the drug 
manufacturers provided further data, but this often had to be evaluated in the 
light of data from other manufacturers and published research data. Opinion 
was not sought at this stage. This was left to the discussion. 
Although it might seem that decisions would be most reliable if only the 
evidence was considered, such an exclusive approach would have been 
neither practical nor helpful. Many areas of primary care still lack a research 
base. Only 1% of the research that is done concerns acute 
illneSS121 
, an 
important area for formulary influence when chronic, especially stable, 
conditions are not so amenable to change of medication. Furthermore, 
perspectives from the patients' and prescribers' viewpoints are under-reported 
in the literature. For example, at the meetings about drugs applied to the skin, 
samples were provided so that the participants could literally assess the feel 
of the product as no suitable data was found. Our sample of participants was 
not large enough for statistical validity, nor were the products used to cure any 
disease present. The test was a single smear, not a period of use. Overall, 
hardly a good assessment, but better than ignoring the issue of acceptability 
to patients. 
It was also interesting to hear views from the experience of prescribers on 
how medications should be seen in the context of the social circumstances in 
which they are used. One young GP puzzled the group by blandly stating that 
it was unwise to prescribe lemon and lime Dioralyte, as though it was self- 
apparent. When others asked why, she explained that parents commonly 
believe that green vomit signifies a more serious illness in a young child or 
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baby than other colours. Furthermore, they are correct because the 
BabyCheck system supports this by scoring green colour higher. Lemon and 
lime Dioralyte colours the stomach contents green and therefore prescribing 
this flavour can cause unnecessary concern and a repeat contact for medical 
help. This is one example of the invaluable added value that came from the 
discussions which would never have been found among the published 
literature. Pure evidence-based formularies would have a publication bias, 
which would not be so helpful to prescribers. 
A second example illustrates how professional tips in prescribing can be 
shared. Quinine bisulphate is included in the formulary not for any particular 
therapeutic advantage of this salt of quinine over any other, but because there 
is no quinidine bisulphate, only sulphates of both quinine and quinidine are 
available. Habitually prescribing the bisulphate for nocturnal cramp reduces 
the risk of the wrong drug being prescribed or dispensed. 
Following the discussion on a therapeutic subgroup the chairman summarised 
the conclusions and asked participants to decide which drugs should be 
included in the formulary. An item was included if either: 
" it had been short-listed and no-one had recommended exclusion 
" it had been proposed and achieved a simple majority vote at the meeting 
Recording the discussion 
I chaired all the meetings. Neither the resource people nor I voted. My main 
task was to record the reasons for the decisions made by the group at the 
meeting in order to transfer this information into the formulary notes. An 
independent record was kept by the project administrator to verify that the 
formulary correctly reflected the decisions. 
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Dissemination 
Notes from the meetings were formalised and transcribed to a word- 
processed document. To allow for pages to be inserted from future upgrades, 
simple 2-hole loose-leaf A4 binders were used. Indexing was according to the 
classification of drugs in the British National Formulary, with a thumb tab at 
the start of each chapter. Page numbers were avoided. Formularies were 
delivered by hand to each participating practice on, or near, 1 st January each 
year, one copy for each partner. Additional copies were available on request. 
When the nurses created the first draft of the section on wound care, 
additional copies of the full formulary were made available to community 
based nurses. All doctors and nurses working with practices that had 
contributed to the development of the formulary were provided with free 
copies automatically. A few practices within Bedfordshire, and a few in other 
counties, purchased copies. No copies were purchased by practices in the 
North of the county, which formed the second cohort. The price in 1994 was 
E6, which covered the materials used only. 
Towards the end of 1997, a floppy disc was included with the paper version. 
One hundred extra formularies were purchased by the Dunstable and 
Houghton Regis Locality Commissioning Pilot. The cost basis then changed to 
a yearly subscription, which included updates. Previously this had been 
unnecessary because updates would have been automatically distributed to 
participating practices. The cost differential encouraged the uptake of 
electronic formats, which were easier to keep up-to-date: El 0 for a printed 
copy, : E2.50 for a disc. 
In 1999, a GP in the North, who had no previous involvement with the 
formulary, transferred it into WAX, the electronic medical library developed by 
the Cambridge Informatics Group. From here it was a short step to the first 
Hyperlink Text Markup Language (HTML) version. Three upgrades later, the 
current formulary is available in a variety of formats: paper, floppy disc 
document, WAX book, HTML on CID ROM and online. The HTML version is 
the easiest to maintain and is likely to be the format preferred by users 
because of the ease of accessing information on specific drugs or therapeutic 
46 
groups by a few clicks. The online version offers the latest news, can be 
updated continuously instead of periodically, and has virtually no overheads in 
terms of materials required to maintain it. Much wider access is possible, 
although the research presented in this thesis is limited to effect on 
prescribing within the county. No data are available on prescribing effects 
further afield, but in the past year over 1000 visits have been made to the 
online version and the update meetings for the formulary in 2000 have been 
attended by uninvited (but welcome) pharmaceutical advisors to other Health 
Authorities and Primary Care Groups. 
Feedback on prescribing 
Every general practitioner who contributed to the formulary in either the South 
or the North cohort received annual feedback on prescribing during the 
development period, but not subsequently when the formulary was being 
maintained by update meetings. This was largely a matter of necessity. 
Continuing to provide regular feedback for all the doctors and practices in the 
South cohort while preparing and later facilitating the North cohort would have 
overwhelmed the resources of the project. PACT data were not available 
electronically so every item down to the detail of individual prescriptions had to 
be entered on to a computer database even before analysis could begin. Both 
the delegate's individual and practice prescribing were included so that 
partners could have a copy relevant to the practice as a whole, while the 
delegate could see which changes were individual. A sample of the feedback 
is given in Appendix C. 
Combining the formularies 
By 1998, each of the two cohorts had produced and distributed a district 
formulary. The aim of the second cohort in the North had been to see if 
practices with no history of collaborative work would achieve the same effect 
as the first cohort, which had a long history of collaboration. Having completed 
two distinct formularies for primary care, doctors in both cohorts suggested 
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combining the formularies to form the basis for a countywide primary care 
formulary, developed by doctors and nurses over a wide area of Bedfordshire 
Work on this started in 1999, after the conclusion of the evaluation of 
prescribing which relied on using non-participating practices in the county as 
controls. 
Process 
The process to combine the formularies involved two extra steps, before we 
continued with the same format of formulary development. Step one was a 
focus group of five GlPs and one nurse from the South cohort discussing the 
differences between the two formularies, comparing the more up-to-date North 
formulary with the older South formulary. Data on this are presented in the 
results section. Items that had been included by the North cohort that were 
very similar to items previously included by the South cohort were briefly 
discussed with a view to the North's choice being adopted by the South. Often 
there was a clear answer, for example a product that had come off patent and 
available generically. This process resolved minor differences. All others were 
deferred to a meeting conducted in the style of the normal formulary 
development meetings, but one with the specific aim of combining the two 
formularies. 
Special meeting 
Drugs were not proposed or recommended for exclusion prior to this special 
meeting; the proposals consisted of any drug or wound care product that 
appeared in only one of the two formularies. The logistics of holding this 
meeting changed the nature of all subsequent meetings. Suddenly there were 
twice as many practices involved, and the higher profile of the formularies had 
attracted more doctors and nurses to help with ongoing development. 
Instead 
of 20-25 people attending, there were 75. The list of items to be considered 
was also bigger for this special combining meeting. The research posed 
little 
problem because it had largely been done. The South cohort items required 
some updating of information. It would have been impractical to present 
information to the whole group within one evening meeting. Instead, several 
pharmacists were recruited to facilitate smaller group discussions, each group 
taking a few therapeutic groups. There was an initial presentation for 
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newcomers about the history and aim of the formulary and an explanation of 
the group work. Most of the evening was taken up with the group work, 
followed by a brief drawing together of what had been decided by each group 
facilitator. All notes were collated to form the changes that needed to be made 
to the formulary notes regarding reasons for inclusion of selected items. 
Four pharmacists and one nurse were the facilitators. I chaired the meeting, 
visited the small groups in turn, recorded the decisions, collected the 
facilitators' notes and created the first combined county formulary from these. 
The meeting was held in the large postgraduate medical centre at Luton. 
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Measurement of prescribing 
Full prescribing data were obtained with consent from all partners in the 20 subject 
practices for the relevant first quarters of the years 1991 - 1998. This includes one 
year's data prior to the formulary development for each therapeutic group. The 
longest series was for 8 years, in the case of the first three therapeutic groups 
considered by the South cohort: cardiovascular, respiratory and musculoskeletal. 
One practice had to be excluded from analysis because one of the partners did not 
consent to release of prescribing data. The delegate from this practice continues to 
play an active role in the formulary development. The Health Authority 
pharmaceutical advisor gave consent to release the aggregated county prescribing 
data. The project administrator transferred data for analysis on to computer. Cross- 
checking for accuracy was done by comparing totals of the entered data with totals 
listed in the PACT data summary. 
Details of the method by which practices were compared with control levels are fully 
described in Appendix D, recently submitted to the British Journal of General Practice 
for publication as a paper entitled 'Measuring changes in primary care prescribing - 
traps for the unwary and how to avoid them'. In summary, control data was obtained 
by subtracting the subject practices' data from the county total to give aggregated 
data for all non-participating practices in Bedfordshire. This control data was used to 
create demand factors for each therapeutic group, for formulary drugs and non- 
formulary drugs. For example, the North cohort, who developed a formulary for drugs 
in 12 chapters of the British National Formulary plus Wound Care products in the 
appendix, would have 26 (2xl 3) demand factors. Another factor was needed to 
adjust for differences in list size. These factors were applied to the prescribing data of 
each practice, in order to estimate the expected prescribing of each practice the 
following year. Match-pairs were compared for each year, a subject practice 
compared with the same practice's expected prescribing in the same quarter year 
and for the same therapeutic group, divided into formulary item group and a non- 
formulary item group. Only after these matched pair comparisons were made, were 
the data totalled to show the overall picture. This provides a better use of control data 
to match practices' existing prescribing with expected prescribing, than comparisons 
the with Health Authority equivalent practices before and after the 
formulary. Full 
details and a worked example using real data can be found in appendix 
D. 
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Units of prescribing and list size 
Under the subtitle of 'The Difficulties' in Appendix D, the particular problems of items 
and list size are covered. These are important enough to make it worth inserting the 
text here. 
What are we counting? 
The item can be any size. 
A prescription for one item can be anything from a single tablet to a six-month supply. 
The difficulties in using such a variable unit have been the subject of entire papers 
122 
. 
Defined daily doses offer an alternative 123,124 . 
The choice depends on the 
question being asked. If volume of prescribing and cost analysis are central to the 
study, defined daily doses may be better If it is the activity of prescribing that is 
central - the choice of drug, the decision to prescribe - rather than how much, then 
the item may be a more appropriate unit. 
List size. 
Notorious for causing difficultieS51 . 
This is the denominator for a/I the fractions often 
quoted where a parameter is expressed relative to the list size of a practice. Rather 
than simply using the number of patients, a formula to calculate prescribing units 
(PUS 125 orASTROPUs 126 or STARPUs 12') is usually used in an attempt to 
compensate for the fact that certain groups of patients require more medication than 
others. Despite these improvements, list size remains one of the biggestjokers in the 
data pack. Prescribing is not simply related to the number of patients in a linear way, 
but influenced by the demand for treatment and the availability of doctors to 
prescribe. A partner retiring and not being replaced for several months could have a 
major impact on prescribing despite a steady list size. Such events happen often 
enough to disrupt studies involving a small sample of practices. Bizarre swings 
in the 
supposed prescribing are usually found to be an artefact of a sudden change 
in list 
size, such as a practice taking over the list of a closing practice. 
Despite these problems, the units of prescribing used in this study were 'items', as 
explained above, and the units of list size were prescribing units, 1 unit for every 
registered patient or temporary resident under the age of 65,3 units for anyone older. 
These are the reasons why. 
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no standardised daily defined doses exist for the wide range of drugs in the 
formulary 
formularies are selective lists, primarily aimed at informing the choice of drug, not 
the amount prescribed 
0 prescribing units are still used in PACT reports, the source of all the data 
* ASTROPUs and STARPUs were not available for practices at the start of the 
study 
9 changing units mid way through the study was undesirable 
Statistical method 
Sample size 
It would be normal to set a sample size at the very start of a project. The sample size 
for each cohort was checked as soon as the 12 practices of the South Bedfordshire 
Practitioners' Group had agreed to take part and all but one doctor had signed 
consent to allow access to prescribing data. The initial data in 1991, prior to the 
formulary intervention, allowed calculation of the variance in the numbers of items 
prescribed and costs, for the samples of 11 practices. This sample size would detect 
a 4% change in the subject practices relative to control in volume of prescribing, and 
a 4.4% change in the cost at a significance of p<0.05. These were considered 
acceptable levels. If they had been higher, more practices would need to have been 
invited. 
In the North, the aim was to enrol 13 practices to bring the detection of cost 
difference down to 4%. When only 9 joined despite a presentation at the medical 
institute in Bedford, a close decision was made to continue with the development of a 
formulary for the North of the county despite the small sample size. Shifts of 4.4% for 
prescribing and 4.8% for cost would be detected. Even if no significant effects were 
observed, the practices might later co-operate with the South cohort to enlarge 
the 
sample. 
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Tests of significance 
One advantage of the method described in Appendix D is that it facilitates the use of 
matched-pair Mests, generally considered to be a robust test of significance 
applicable to data that has an approximately normal distribution. Support for the tests 
of significance was obtained by displaying 95% confidence intervals on the graphs, 
corresponding to the p values from the matched-pair Mests. The non-parametric but 
less powerful Wlicoxon signed rank test was also used on a sample of the South 
cohort data in case some distributions deviated from normal sufficiently to interfere 
with the Mest but no discrepancies were found. 
Limitations 
Are the results generally applicable? 
The main limitation of this study is that it was conducted in one location, had an 
enthusiastic leader and a team of dedicated supporters. There is no evidence 
presented here that effects of developing a formulary elsewhere would be similar. 
Multi-faceted intervention 
The method cannot show what it is about formulary development that has any effect 
on prescribing. This intervention has many facets: educational, social, peer-review, 
evidence-based medicine, multiprofessional input, academic links, documented 
prescribing advice, online access, integration with practice computer systems. Any of 
these could have an impact on prescribing. 
Assumption in use of control data 
Using control data assumes that the subject practices respond to demands 
for 
medication similarly to other practices in the county that were not involved 
in the 
formulary project. This is perhaps the best estimate that can be made, but the control 
data cannot be an excellent match for the subject because the practices were self- 
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selected, and therefore more likely to have an interest in prescribing issues than 
others. 
The two cohorts were treated as independent projects in obtaining control data. In 
other words, the control for the North cohort was simply the totals for the county 
minus the subject practices in the North cohort. No adjustment was made for the 11 
practices in the South cohort. An adjustment could have been made by subtracting 
all 20 subject practice's data from the county data of 93 practices, to give a control 
level for all 73 non-participating practices. This would have answered the point that 
the second cohort was likely to adopt much of the South's formulary because it was 
used to create the shortlist of initial proposals. However, it was not known if this 
would happen or not. Furthermore, it would exacerbate the degree of mismatch 
between the controls and the subjects because even fewer practices with a particular 
interest in therapeutics would be left in the control group. The choice was made on 
the grounds that by treating the cohorts independently, any differences between the 
subjects and control would be slightly less than if both cohorts were excluded from 
the control group. Thus any positive result suggesting an effect of the formulary 
would be slightly more robust, but a negative result of no effect slightly less robust. 
This was the preferred way round. 
Limitations of prescribing data 
Many of the limitations are described in Appendix D. The most important one is that 
aggregated data on prescribing is a poor indicator of whether prescribing is 
appropriate. For this, clinical information must be matched to prescribing 
I information"' 
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Originality 
Many previous studies on ways to influence prescribing have been reported. This 
one follows the standard method of using prescribing data to assess the impact of an 
intervention. Some features are somewhat unusual 
wide involvement of local general practitioners and community nurses 
follow-up of up to 8 years prescribing 
a formulary section on wound care 
* electronic formats and online access 
Some of these aspects may have been why the project was awarded an NHS 
Beacon Award in 1999 and 2000. 
Funding 
Overall income was E40,000 in grants and E1,500 in sales. 
Funding 
Year E Source 
1991 16,000 NW Thames Regional Health Authority 
1992 10,000 NW Thames Regional Health Authority 
1993 2,400 NW Thames Regional Health Authority 
1995 2,175 Transferred from residual research funds from other projects 
1996 5,000 Bedfordshire Audit and Education Group 
1997 5,000 Royal College of General Practitioners 
1998 4,700 Bedfordshire Health Authority 
1999 4,700 
1,400 
Bedfordshire Health Authority 
Dunstable and Houghton Regis Locality Commissioning Pilot - bulk 
purchase of formularies 
2000 - Free secondment of resources from 
five Primary Care Groups 
Table 9. Funding of the project 
Funding has come entirely from grants for research and development, with a smaller 
contribution from the proceeds of formulary sales. There was no sponsorship of the 
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formulary development by the pharmaceutical industry. Sponsorship of medical 
meetings can weaken the message of independent drug information 128. Furthermore, 
participants were asked not to see representatives about drugs that were to be 
discussed at the next formulary meeting, for fear of introducing bias into the 
discussions. 
Since the formulary has become countywide there have been a few incidents relating 
to the influence of the pharmaceutical industry which may be of help to future 
formulary developers. The method used to propose items to be included in the 
formulary is robust in that it is limited to NHS staff, that evidence behind proposals is 
sought by pharmacists independent of both the industry and of profits resulting from 
the sale of items, and that I as the chairman take a leading but non-voting role. 
Despite this, one enterprising representative, on learning that the prescribing lead of 
one large Primary Care Group in Bedfordshire was no more able than anyone else to 
influence the content of the formulary, visited seven single-handed GPs in the area 
and supported their proposal forms for one particular drug by suggesting how the 
form could be filled in and offering to deliver it. Thus we received seven very similar 
proposals for one drug, all from GPs who may not have been aware of their 
colleagues' proposals. The process survived the attack without intervention. The 
evidence was researched as usual by the pharmacists, presented at the meeting, 
and there was not a single vote to include the drug from the 50 people in attendance. 
It took some persuasion before the Primary Care Group pharmacists would accept 
that the formulary could be online available over the Internet. Their preferred option 
was to wait until NHSnet limited access. Their concern rested on precedents in the 
United States where information provided by pharmacists about drugs has resulted in 
libel actions. The pharmacists in Bedfordshire have somewhat reluctantly accepted 
the need to use the Internet after being reassured that 
no individual pharmacist can be identified as the source of the information 
" the formulary represents a record of meetings, not a statement of 
fact 
"a disclaimer to this effect is included on the website 
They were the only group of support people who asked for their names not to be 
included in the acknowledgements online. 
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Results 
South Cohort 1991 - 1998 
Participants 
Out of 300 general practitioners in Bedfordshire, 50 participated and the remaining 
250 formed the control group. The participating doctors were from 11 urban and 
semi-rural practices, covering Luton, Dunstable and the surrounding rural areas and 
villages. Twenty-six general practitioners attended at least one of the formulary 
meetings and every practice had at least one participating partner. Everyone 
received copies of the formulary and all but one provided their level-3 PACT data for 
analysis. The practice with a dissenting partner could not be included in the analysis. 
Two practices dispensed a minority of their prescriptions. 
There was only one change in the age/sex profile of the subject practices when one 
took on a university health commitment. During the study 2 (18%) of the 11 subject 
practices became fundholding (both in April 1993), as did 12 (13%) out of the 95 
practices in the county. 
Data nearest to the time when practices were invited, is for lt January 1992, when 
the prescribing list sizes ranged from 6,366 to 16,056 prescribing units, with a mean 
of 11,063 and a total of 121,697. A list of prescribing list sizes is given in Table 10. 
Formulary 
Initial results from the project were published in 1996" Appendix E, when the 
formulary consisted of brief notes on the selection of 179 drugs and drug delivery 
devices, 72% of which were specified by generic name. Only two formats were 
available: a printed, loose-leaf, thumb-tabbed document and a disc of the word- 
processed document. After the first full review meeting, a new section was added, 
which formed an appendix, listing all the entries that had been deleted 
from the 
formulary and the reasons why. 
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Prescribing 
Volume 
Figure 1 shows the volume of prescribing of the 11 subject practices relative to the 
expected level derived from control data. A negative result means the subject 
practice reduced the number of items prescribed relative to control. The only 
comparison to reach significance was an 11 % reduction in the number of items 
prescribed in the musculoskeletal group in 1994. All but three of the comparisons 
show the subject practices reduced their prescribing across all therapeutic groups, 
but the shifts are small relative to the confidence intervals. This is confirmed by 
Figure 2, showing the overall number of items prescribed. 
Choice of drug 
Significant changes in the choice of drug occurred in three out of twelve therapeutic 
groups: cardiovascular, musculoskeletal and, for 1993 only, obstetrics and 
gynaecology. The greatest change occurred in 1992, when the prescribing in the 
musculoskeletal therapeutic group shifted towards drugs in the formulary by 13.9% 
more in subject practices than in controls. All changes occurred immediately after the 
development and distribution of the formulary. Generic prescribing in the subject 
practices increased from 44% in 1991 to 51 % in 1994, similar to the control practices, 
which increased from 40% to 48%. Figure 3 gives proportion of formulary items 
prescribed to total number of items prescribed for the first quarter of each of the 
study years, with means, 95% confidence intervals and the result of the matched-pair 
Mests. A positive result represents a shift towards use of formulary drugs. 
Figure 4 is a simpler representation of the data without statistical information being 
presented. For the three therapeutic groups considered in autumn 1991, that is 
cardiovascular, respiratory and musculoskeletal, each graph charts the proportion of 
prescribing that was for an item in the formulary. Red circles represent the subject 
practices, blue triangles the controls. 
Figure 5 and 6 show the results for the therapeutic groups covered in autumn 1992 
and included in the formulary distributed on ls'January 1993. Figure 7 gives 
the 
results for the next year, ending in distribution of the first complete formulary on 
1't 
January 1994. 
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Figure 1. 
Volume of prescribing by 11 practices 
in South Bedfordshire relative to 
expected level derived from control 
data. Mean and 95% conf i dence 
interval for first quarter of each year. 
60 
17 Z 
0 
M 
-a Ir) 1. i r-, 
-93 
-94 
-95 
-96 
-97 
-98 
Figure 2. 
Volume of prescribing by 11 practices in South Bedfordshire in all therapeutic groups relative to 
expected level derived from control data. Mean and 95% confi dence interval for first quarter of 
each year. 
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Figure 3. 
Proportion of prescribing by 11 practices 
in South Bedfordshire for items in the 
formulary, relative to expected level 
derived from control data. Mean and 
95% confi dence interval for first quarter 
of each year. 
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Proportion of prescribing for items in the formulary by 11 practices in South 
Bedfordshire. Control data from the rest of the county. Therapeutic groups 
covered by the formulary distributed on 1 st January 1992. Mean; 
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Figure 5. 
Proportion of prescribing for items in the formulary by 11 practices in South 
Bedfordshire. Control data from the rest of the county. Therapeutic groups 
covered by the formulary distributed on 1 st January 1993. Mean 
for first quarter of each year. 
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Figure 6. 
Proportion of prescribing for items in the formulary by 11 practices in South 
Bedfordshire. Control data from the rest of the county. Therapeutic groups 
covered by the formulary distributed on 1 st January 1993. Mean, 
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Figure 7. 
Proportion of prescribing for items in the formulary by 11 practices in South 
Bedfordshire. Control data from the rest of the county. Therapeutic groups 
covered by the formulary distributed on 1 st January 1994. Mean, 
for first quarter of each year. 
Practices 
Corytrol 
66 
1 
Overall changes in prescribing choices across all therapeutic groups show a shift in 
the subject practices, relative to controls, towards using items in the formulary 
between 1992 - 1995. The first two years reach significance on a one-tailed Mest at 
p<0.01. Thereafter no significant differences are seen. Figure 8 displays these 
results. 
Cost 
Savings occurred in subject practices relative to the prescribing cost of control 
practices. Significant levels were reached in four therapeutic groups. Three 
correspond to the groups where there was a shift in the choice of drug, 
cardiovascular, musculoskeletal and obstetrics and gynaecology. Changes in cost 
coincide with changes in choice, with the exception of the single change in obstetrics 
and gynaecology where the choice shifts immediately after the formulary in 1993, but 
costs remained unchanged until 1996. Figure 9 shows the changes in total drug 
costs for all 11 subject practices relative to controls, in thousands of pounds Sterling, 
for the first quarter of each year. Mean, 95% confidence intervals and the results of 
the matched-pair t-tests are shown. 
Overall changes in prescribing costs across all therapeutic groups shows a saving by 
the subject practices, relative to controls, between 1992 - 1995, the same years as 
the change in choice of item. The first two years reach significance on a one-tailed t- 
test at p<0.01 for 1992 and p<0.05 for 1993. Thereafter no significant differences are 
seen. Figure 10 displays these results. 
Data for Figure 10 are in the row labelled 'Practices' in Table 11. The total saving in 
the January - March quarters only, over seven years 1992 - 
1998 inclusive, is 
E49,307. This equates to a mean saving of : E51 9 per practice per quarter year. 
Mean costs of formulary and non-formulary items are shown in Figure 11. The data 
for the graph are in Table 12. A rule of halves applies. Items in the formulary cost half 
that of non-formulary items at the start of the project in 1991, E4 per item as opposed 
to E8. Over the course of the project, the price of formulary items increased at half 
the rate of the non-formulary ones, rising 25% as opposed to 50%. 
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Figure 8. 
Proportion of prescribing by 11 practices in South Bedfordshire for items in the formulary in all 
therapeutic groups, relative to expected level derived from control data. Mean and 95% confidence 
interval for first quarter of each year. 
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Figure 9. 
Prescribing costs of 11 practices in 
South Bedfordshire relative to expected 
level derived from control data. Mean 
cost for first quarter of each year. 
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Figure 10. 
Quarterly prescribing costs of 11 practices in South Bedfordshire relative to expected level 
derived from control data. Totals and 95% confi dence interval for first quarter of each year. 
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Who was affected 
Doctors who attended any of the meetings to help develop the formulary changed 
their prescribing more than their partners, who in turn changed their prescribing more 
than the control group in the therapeutic groups where the formulary had an effect. 
Figure 12 shows this for the choice of drug, the proportion of formulary items 
prescribed to total number of items prescribed. Higher levels indicate greater 
acceptance of the formulary. 
North Cohort 1996 - 1998 
Participants 
Nine practices with a total of 43 partners responded and took part in a series of 
workshops in 1996 and 1997, using the same format as previously used in the South. 
Thirteen general practitioners attended at least one of the formulary meetings and 
every practice had at least one participating partner. In 1997, their prescribing list 
sizes ranged from 4929 to 16043 prescribing units, with a mean of 11431 and a total 
of 103373, covering areas within the county town of Bedford and the surrounding 
more rural towns and villages. Unlike the South Bedfordshire Practitioners' Group, 
these practices did not have a history of collaborative work. A full list of prescribing 
list sizes is given in Table 13. 
The prescribing of the 9 subject practices was similar to the control group prior to the 
formulary. For the therapeutic groups considered in 1996 the average number of 
items per prescribing unit was 0.66 for both the subject practices and the control 
practices, and the cost per prescribing unit per quarter year was F-6.73 for the subject 
practices and : E6.67 for the control practices. 
Formulary 
The first complete formulary included 245 entries, similar in style to the South version 
with notes on each entry to explain the reason for the inclusion. A section on wound 
care was included, accounting for some of the increased size over the first complete 
formulary for the South, which contained only 179 drugs and drug delivery devices. 
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Figure 12. 
in the formulary Proportion of prescribing for items by 26 delegates who 
developed the formulary and 24 of their partners from 11 practices in South 
Bedfordshire. Control data from the rest of the co u nty. The rape utic groups 
covered by the form_ulary distributed on 1 st January 1992. Mean 
for first quarter of each year. 
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Dr LN 174 276 11 54F',, Dr EN & partners 4845 4929 5047 
Dr FN 1508 1414 1313 
Dr BN & partners 10568 10234 10705 
, 
Dr RN 
lDr KN 
3909 
1034 
3742 
15192 
3713 
1493 
lDr ON & partners 11785 12070 12386 
lDr BN 242ý =2352 1883 
Dr HN 2243 2113 1-6-7-63-] 3 
Dr MN & partners 
- 
13961 13803 137-1 ý811 
ýID 
r SN 1 2447 2294 2204 
IlDr NN & partners 8107 8322 8588 
Dr DN 17 169 341 
Dr LN & partners 16126 1 16043 16140 
lpr AN 3584 11 3443 3513 
Dr JN 1927 2281 2287 
jDr WN 540 2263 2348 
ýDr IN & partners 14458 14466 14594 
iDr UN 2546 2637 2495 
1 
, Dr CN & partners 8918 9395 9849 
lDr TN 3125 3010 2883 
! Dr FN & partners 14119 14111 14156 
ýBedfordshire 735741 742093 747815 
ýTotal of Practices 102887 103373 105183 
Control (Beds- Practices) 632854 638720 642632 
otal of Delegates 25480 27286 26690 
1'rotal of Partners (Practices- Delegates) 77407 1 76087 78492 
Table 13. 
List sizes in prescribing units. 13 delegates who developed 
the formulary from 9 practices in North Bedfordshire. 
7(o 
Formats were initially the same, printed copy and disc document, but work on other 
electronic versions started as soon as the formulary was finalised. 
Prescribing 
Voiume 
Only small changes were observed, of which the largest two reductions and the 
largest two increases were as follows. Relative to control levels, subject practices 
prescribed 1.1 % fewer items per prescribing unit for infections, and 0.3% fewer for 
neurological items. Increases were seen of 1% in the endocrine group, and 0.5% in 
the obstetrics and gynaecology group. There was no apparent overall tendency for 
subject practices to prescribe either more or less than controls. 
Choice of drug 
Significant changes in the choice of drug occurred in five out of thirteen therapeutic 
groups: respiratory, infection, musculoskeletal, ear nose and throat, and skin. The 
greatest change occurred in 1997, when the prescribing in the musculoskeletal 
therapeutic group shifted towards drugs in the formulary by 13.5% more in subject 
practices than in controls. All changes occurred immediately after the development 
and distribution of the formulary. Figure 13 gives proportion of formulary items 
prescribed to total number of items prescribed for the first quarter of each of the 
study years, with means, 95% confidence intervals and the result of the matched-pair 
Mests. A positive result represents a shift towards use of formulary drugs. 
Cost 
Savings occurred in subject practices relative to the prescribing cost of control 
practices. Significant levels were reached in three therapeutic groups: respiratory, 
infection and musculoskeletal. Changes in cost coincide with changes in choice. 
Figure 14 shows the changes in total drug costs for all 11 subject practices relative 
to 
controls, in thousands of pounds Sterling, for the first quarter of each year. 
Results of 
the matched-pair Mests are shown. 
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Figure 13. 
+10 +20 % 
Proportion of prescribing by 9 practices in North Bedfordshire for items 
in the formulary, relative to expected level derived from control data. 
Mean and 95% confindence interval for first quarter of each year. 
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Figure 14. 
Prescribing costs of 9 practices in North Bedfordshire relative to expected 
level derived from control data. Mean cost for first quarter of each year. 
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Total prescribing costs for the 9 subject practices were El 3,000 lower than expected 
costs derived from controls in the first quarter of 1997, when only 4 therapeutic 
groups had been considered, including two of those that showed savings: respiratory 
and musculoskeletal. Subject practices costs were E27,000 lower in the first quarter 
of 1999, when all therapeutic groups had been discussed. 
Combining the formularies 
North and South 
Overall the take-up of the formulary was 21 (23%) out of 93 practices and 93 (31 %) 
out of 300 general practitioners, of which 39 helped develop the formulary. 
Approximately 50 community nurses were involved. 
Practices in the North adopted 79% of the formulary chosen by the practices in the 
South defined as exact or near matches, declined 21 %, and added 100 different 
items. The South formulary was used as the shortlist of initial proposals for the North 
formulary. Table 14 and Figure 15 show more details of the comparison. A full list of 
the entries in each formulary in March 1998 is given in appendix F. Differences 
between the two formularies are underlined. 
Integration with wound care education 
While the formularies were being combined, a countywide education programme was 
set up to improve the skills of district nurses in the management of wound care. Many 
products require specialist training in their use. Nurses who were helping to develop 
the formulary included 25 entries, but more items were recommended by the 
education programme, which needed to be more inclusive than the formulary aim of 
80% prescribing. In April 2000, the educational formulary was combined with the 
county formulary by the addition of 22 items and the deletion of 4 items out of 
the 
original 25. Details of this are given on the CDROM accessed from the home page 
under"Wound Care Section revised 25 
th April 2000", click on "What's new". All the 
changes were considered minor and undertaken by a focus group, consisting mainly 
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North South 
Exact matches 132 54% 159% 132 72% 179% 
Near matches 13 5% 13 7% 
Unmatched entries 100 41% 38 21% 
Total No of entries 245 100% 183 100% 
Table 14. Comparison of entries in the two formularies 
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Figure 15. Correspondence of items in the North and South formularies. 
The darker the columns, the more the agreement between the two formularies 
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of nurses with specialist knowledge of wound care and pharmacists from the Primary 
Care Groups. 
Some new items were included to broaden the range of choices. New subsections, 
such as which dressing pack to use, had been overlooked by the county formulary. 
More controversial differences have been listed as proposals and exclusions for the 
forthcoming formulary wound care review meeting in October 2000. The section has 
enlarged to the point where it needs its own review meeting. Previously it had been 
managed within the general formulary review. 
Data sources 
Formulary 
The complete Bedfordshire Primary Care Formulary is enclosed in the envelope 
bound with this thesis. See appendix A for instructions. It was last updated on 25 th 
April 2000. The latest version is online at www. wlhc. demon. co. uk. 
Prescribing data 
Data required for the graphical representation of the results are needed down to the 
level of details for individual items prescribed by individual doctors. One of the 
spreadsheets to hold the data contains 12,880 cells, and this only covers one 
therapeutic group, for one cohort, for half the duration of the project. It would 
therefore be impractical to include all the data in this thesis, but for anyone who 
would like to make use of the data in re-analysis or for comparison purposes, I can 
provide it. Contact me at Wigmore Lane Health Centre, Luton, Beds LU2 8BG- 
Example tables are given in Appendix G. 
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Discussion 
Participants 
Practices 
One quarter of practices and one third of general practitioners in the county accepted 
the invitation to develop the formulary. Thus there was a bias towards larger 
practices. The mean prescribing list sizes for the two cohorts were 11,063 for the 
South and 11,431 for the North compared with the county mean of 7800. Twenty-six 
doctors in the South and thirteen in the North contributed personally to the process 
by making recommendations and contributing to the discussions. Most delegates 
came to the all the meetings, one for each of 12 or 13 therapeutic groups, plus 
update meetings, each of at least two and a half hours. Thus a substantial proportion 
of the doctors in Bedfordshire were prepared to make a substantial commitment to 
develop a formulary. 
Formularies are known to be more effective if the prescribers are involved with the 
development"; 71; 72; 129. The Audit Commission recommended that formularies should 
be developed locally by users 18 . 
New national formularies still need local 
implementation, 5; 108 
. 
The collaboration of the participating doctors and nurses in the 
development of the Bedfordshire formulary was broad-based and continues after 
eight years. 
Nurses 
Fifty nurses contributed to the meetings on wound care. No analysis of their 
prescribing was possible prior to recent developments in nurse prescribing. About 40 
were district nurses, the other 10 were practice nurses. The push to include a section 
on wound care came from the nurses who heard about the formulary for drugs. 
Nurses expert in wound care facilitated meetings. Personally I discovered the 
greatest gap in my knowledge of prescribing at these fascinating meetings. Many of 
the delegates commented on this. They had become accustomed to attending 
formulary meetings, so the turn out for meetings on dressings and related products 
was well attended by the doctors, something which I know from my experience as 
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GP tutor would not have happened if such events had been arranged independently 
of the formulary project. 
If the transfer of knowledge and ideas at these meetings on wound care was fertile 
educational ground for the doctors, so too were the general formulary update 
meetings attended by both nurses and doctors. Each came for a primary interest in 
either therapeutics or wound care, but the nurses soon started contributing to our 
discussions on the use of drugs. It was interesting to note when doing the systematic 
review that virtually no research has been done on the nursing aspects of 
prescribing. This must surely change with the advent of nurses signing their own 
prescriptions and the increasing role of their profession within primary care. 
With the increasing size of the group interested in maintaining the formulary, sadly 
the joint update meetings are no longer practical, either in terms of the number of 
items needing to be discussed in one evening, or the number of delegates who need 
to be involved in the discussion. 
Formulary 
The formulary itself forms part of this thesis and is included on the CDROM enclosed 
in the envelope. This electronic format in Hyperlinked Text Markup Language, the 
language of the World Wide Web, has proved to be the most popular this year. 
Updates are planned for twice every year and anyone working in the National Health 
Service is welcome to contribute. Dates of the next update meeting can be found at 
www. wlhc. demon. co. uk, where proposals and exclusion recommendations can be 
made online. 
The formularies that were found to influence prescribing in the systematic review 
have changed in format over the past fifteen years. Early formularies focused on 
providing guidance for common conditions seen in primary care 
12; 74; 115; 129 
, 
but this 
role was taken over by more general advice on management in the increasing 
number of guidelines being produced in the 
1990S3 
. 
Formularies became more 
pharmacological in their approach, concentrating on drugs not diseases'09-1 
12; 130-134 
The great advantage of using an electronic format is that the same information can 
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be navigated as a set of management guidelines or as a pharmacological reference 
source. So far, the Bedfordshire On-line Formulary is indexed according to the 
pharmacological classification of drugs. The next step in its development is to 
encourage the formulary groups to consider the information from a clinical angle, 
while the pharmacists continue to support the drug information. This will no doubt 
identify many aspects of the use of drugs which have not so far appeared in the text 
of the formulary. The aim will be to keep each section as short as possible, but 
improve access to each section by smart indexing with hyperlinks. 
Prescilbing 
Volume 
The formulary developed by the South cohort appears to reduce the volume of 
prescribing slightly. The number of items prescribed per prescribing unit by the 
subject practices goes down relative to control levels for almost all therapeutic 
groups. Only one change showed any significance, and this is likely to be because of 
the number of tests done. No significant effect on volume is found on the overall 
volume either. No bias towards a reduction in volume was seen in the North. 
Formularies are selected lists of drugs. Their main aim is to inform prescribing 
decisions, particularly to fill the gap which cannot easily be covered in basic medical 
training when the choice of which angiotensin converting enzyme inhibitor to use is 
considerably less important than knowing when to use one and why. Volume of 
prescribing is less of an issue than choice of drug when a formulary is used, although 
formularies, especially those limited to one group of drugs such as antibiotics, have 
been used in an attempt to reduce overall prescribing and CoStS12; 
90; 115; 135 
. 
No 
recommendations about repeat prescribing are included in the Bedfordshire 
formulary because it is primarily a pharmacological information source, not a 
management tool. It is possible that the discussions on the formulary would 
influence 
doctors to avoid prescribing a drug because of lack of efficacy or side effects. A non- 
pharmacological alternative treatment might be tried instead, or no treatment at all. 
One feature of the results on prescribing shown in Figure 1 is worth noting. There is a 
sudden reduction in the confidence interval between 1992 and 1993. This 
is the 
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group that showed the greatest shift in the choice of drug. The partial formulary was 
distributed on 1't January 1992, so the first bar represented the confidence interval 
for the three-months immediately after the formulary was received. Delegates would 
have known what was going to be in the formulary, but partners probably would not. 
Perhaps the wide confidence interval in 1992 is because smaller practices, with 
most, or one with all, partners being developers, shifted their prescribing straight 
away. In larger practices, where only one or two partners were developers, little 
change would occur until the partners had read the formulary or talked with the 
developer partner. This could explain an enhanced divergence of prescribing 
volumes, followed by a contraction the following year. 
The conclusion from the data must be that there is no significant effect of the 
formulary intervention on prescribing volume. 
Choice of drug 
Therapeutic groups affected 
A shift towards using drugs listed in the formulary was seen in the South in the 
cardiovascular, musculoskeletal and obstetrics and gynaecology groups. The largest 
change was seen in the musculoskeletal group in both cohorts. This short chapter of 
the formulary, contains five non-steroidal anti-inflammatory drugs and four other 
drugs: prednisolone, Depo-Medrone, allopurinol and quinine bisulphate. 
Prednisolone can be discounted from the changes seen in the musculoskeletal group 
because it also appears in the endocrine group. To avoid counting the same items 
twice, all prescribing for prednisolone was measured under the endocrine section. 
The main drugs of the musculoskeletal group in the formulary are the non-steroidal 
anti-inflammatory drugs. These are commonly prescribed in primary care, both for 
acute muscle or joint inflammation, and chronic conditions such as arthritis. The 
acute conditions are short in duration and provide an opportunity for doctors to 
prescribe from a wide range of agents listed in the British National Formulary without 
presenting problems for the patient by way of any change from a previous drug. 
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Non-steroidal anti-inflammatory drugs 
The pharmacists described the well-known ladder of increasing potency and 
increasing side-effect risk 136 , 
but for any particular level of potency there is little 
evidence to say that one drug has a significant advantage over the others available. 
(The recent advent of drugs that selectively inhibit cyclooxygenase-2 may change 
this. ) The five that were selected gave an adequate range of potencies at reasonable 
cost. This clarity of evidence gave an opportunity for doctors to change their 
preferred drug to one in the formulary, without presenting problems to the patient by 
way of a change in their usual medication. Many doctors were surprised and 
interested to learn that after application of a transdermal anti-inflammatory drug to 
one knee, the concentration of drug in the synovial fluid of each knee was very low 
and much the same on the two sides. Transdermal application may occasionally be 
useful for superficial inflammation, but there is no deep penetration 137 . This may 
have 
caused a shift away from transdermal formulations, none of which were included in 
the formulary. The effect would be to show a swing to favour drugs in the formulary 
and a reduction in total costs. Other researchers have found it possible to influence 
the choice of non-steroidal anti-inflammatory drug S72; 1", even if the volume of 
prescribing remains largely unaffected 138 . 
Oral contraceptives 
The shift towards the formulary items in the obstetric and gynaecology group 
probably occurred for different reasons. Here the dominant subgroup of commonly 
prescribed drugs is the oral contraceptive section. Prescriptions are usually issued 
for 3 months' supply initially and 6 months' supply thereafter. Patients who required a 
repeat prescription would be seen once every six months, so the chance of a doctor 
seeing a patient in the first quarter of the year when the prescribing data were 
collected is only 50%. Against this is the high number of women who take the oral 
contraceptive. Many patients would have been seen during the three months, 
although only a proportion of them would have required a change in their normal 
contraceptive. The large number of consultations involved increase the chance than 
we would see an early shift towards use of contraceptives listed in the formulary than 
if the opportunities for change had been fewer. A slight shift towards the formulary in 
this therapeutic group is seen in the North too, but the cohort was smaller in size, and 
no significance is attached. 
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The sudden increase in the use of oral contraceptives in the formulary between 1995 
and 1996 by both the subjects and controls is probably as a result of the media 
announcement on 1 9th October 199 5 linking third generation combined oral 
contraceptives with thrombosis. The formulary was updated at a review meeting after 
the announcement. In 1995 the combined oral contraceptives in the formulary were 
Femodene, Minulet, Marvelon and Logynon. At the review meeting in late autumn 
that year, Microgynon 30 and Cilest (the only third generation pill not tested in the 
study on risk of thrombosis) were added. The professionals who attended that review 
meeting decided not to remove any of the previous selection. To do so was 
considered an over-reaction to a media scare and that many women already taking 
one of the named pills would wish to continue. 
By the time the North cohort considered the issue, they decided to invite an expert on 
contraception to facilitate the discussion on what they saw as an important issue for 
the formulary: guiding prescribing decisions from the evidence while accepting that 
the pill users views were important and would be coloured by the media attention. 
The North's decisions were later to be adopted by the South cohort. The latest 
edition of the formulary reflects this history of changes in its current selection: 
Loestrin 20, Mercilon, Brevinor, Microgynon 30, Marvelon, and Cilest. 
Choices in other therapeutic groups 
Cardiovascular drugs were prescribed more in accord with the formulary in the South 
cohort only. In The Netherlands, many cardiovascular drugs are initiated by 
specialists and continued by G pS139 , 
but conventions of prescribing may be 
somewhat different in Britain. The shift towards the formulary drugs was modest 
compared with some other groups such as musculoskeletal and ENT, but the tight 
confidence intervals show a significant effect. The effect is less marked immediately 
after the formulary, increasing over the next two years, before gradually subsiding. 
This may correspond to drugs in this group being used long term for conditions such 
as hypertension and ischaernic heart disease. 
Changes in the North towards the use of formulary drugs coincided with those in the 
South for the musculoskeletal group only. The other groups that showed a significant 
shift in prescribing choices in the North were respiratory, infection, 
ENT and skin. 
This represents 5 out of the 13 groups considered. The length of the study period 
was shorter. Some of these changes may be transient, particularly 
the groups for 
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which there is only one comparative year: infection, ENT and skin. Both the infection 
group and the skin group changes only just reached significant levels. This was a 
smaller cohort and with only nine practices it is not surprising that confidence 
intervals are fairly wide. 
Therapeutic group most amenable to rapid change 
The message from comparing the changes that occurred in different therapeutic 
groups is that to see an immediate effect of a formulary, the best therapeutic group to 
target is the musculoskeletal group. Groups that contain drugs commonly used, or 
particularly useful for acute conditions, are more likely to show an early change. 
Choices of drugs used for chronic disease may change, but more gradually. This 
implies that studies shorter than about two years may miss an effect that did occur. 
Time course of changes 
The shifts in choice of drug relative to control disappear after two or three years. A 
clear example is seen in the musculoskeletal group in the South. Here the'14% swing 
towards using formulary drugs, which occurred immediately after it had been 
developed, drops to 4% by 1998. The fall is linear at a rate of 1.6% per year, with the 
exception of 1996 when a dip occurred (see Figure 3). The same rate of decline is 
seen in the respiratory group between 1995 - 1998. It is not possible to make any 
judgement about changes over time for the North cohort. 
Turning to Figure 4, we see that the decline is due to a convergence between the 
control group and subjects. Doctors increasingly prefer drugs in the formulary in both 
the subjects and the controls. This is echoed in some of the therapeutic groups that 
showed no shift in prescribing choices relative to controls, such as the 
gastrointestinal group. The reason for the erosion of the influence of the formulary is 
not that the subjects turn to alternative drugs, but that the changes adopted by the 
subject practices are followed by other practices in the county. 
There are a number of possible explanations for this. The one I would favour is that 
where the formulary has an effect, it is to advance a change in practice that would 
have occurred eventually in any case. The process of developing a formulary, with 
its 
evidence-based approach, its educational content and multiprofessional 
collaboration, can be seen as a way of getting research findings into practice. 
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Although the Primary Care Group pharmacists have now taken over the role of 
researching the evidence and presenting it at the meetings, up to 1999 this work was 
undertaken by one pharmacist, seconded half time to assist the development of the 
formulary, while her main occupation continued at the local hospital pharmacy. She 
had no contact with other practices. It was not the person who persuaded the control 
practices to follow suit in any way, although up to 12 may have been influenced by a 
nurse attending some of the meetings. More likely it was the weight of evidence that 
control practices would become aware of and accept more gradually than the subject 
practices, who had been informed by developing the formulary and perhaps 
convinced of the validity of the evidence in the course of discussion with colleagues. 
There are other explanations. There could have been a diffusion of knowledge from 
the delegates, to their partners, to other colleagues. Prescribing incentive schemes 
started in Bedfordshire in 1995. These were not detailed enough to recommend 
specific treatments until recently94 , but 
instead required practices to reduce overall 
spending. Drugs were selected for the formulary if they were equally effective, safe 
and acceptable as alternatives but cheaper. So a scheme to encourage cost 
reductions may have driven practice towards using the drugs listed in a formulary 
they had never seen. Over the same time period, there was more awareness for the 
need to reduce costs. Practices were being faced with allocations for number of 
referrals, longer waiting times, and a greater public awareness of how the health 
service was dependent on finance and could not meet all demands from cradle to 
gravel". it was a time of a great many changes. Doctors who previously felt 
comfortable defending their prescribing of expensive branded drugs on the grounds 
of quality over generics, may have had to think again. The formulary process had no 
prior intention of favouring generics, but the evidence for cost-effectiveness and 
equivalent quality carried through. Delegates attending meetings in 1992 hotly 
debated the issue, but as time passed, it seemed to matter less and less. By the time 
the cohort in the North started, objecting to generics on the grounds that they were 
substandard imports had changed from being a common concern to a quaint notion. 
Some of the charts in Figures 4-6 show prescribing choices have changed 
considerably over the 1991-1998 period, with no apparent effect of the formulary. 
The bottom chart in Figure 5 shows an increase in the proportion of drugs used to 
treat infection that are in the formulary from just under 50% in 1992 to 75% in 1998, 
nearly reaching the formulary target level. Guidelines on antibiotic treatment, 
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addressing known local sensitivities, were developed in Bedfordshire and first 
distributed to practices in 1994. Although this was done independently of the 
formulary development, the evidence used to support the recommendations was 
from the same microbiology laboratories. The guidelines may have influenced 
practices across the county to adopt similar prescribing to the ones participating in 
the formulary development, but no sudden increase in the use of formulary antibiotics 
is seen between 1994 and 1995. The rate of increase is fairly constant from 1992 to 
1997, only tailing off in 1998. 
The South cohort data show that there was an overall difference in prescribing 
choices between the subject and controls for two years after the development of the 
formulary. This is shown in Figure 8. What this hides is that the changes that 
occurred did not fade, but were followed by the control practices. Thus it would be 
fair to say that the formulary produced a change in prescribing choices with a 
measurable difference between participating and non-participating practices 
sustained over three years. Thereafter the effect of the formulary remains, but non- 
participating practices adopt similar prescribing. 
Baseline differences 
Figures 4 -7 show that the subject practices were prescribing a higher proportion of 
drugs in the formulary before the project started in 1991. This could be because 
practices motivated to volunteer to help develop a formulary might have more interest 
in the evidence supporting good prescribing. Another possibility is that the formulary 
items were chosen to some extent on the basis of what the doctors were used to 
prescribing. The aim of sharing facilitators to research and present the evidence was 
to minimise this effect. 
Appropriate prescribing 
The above discussion is based on the results of the evaluation of the formulary 
intervention, which used data on prescribing separated from clinical context. It has 
been suggested that the variation in prescribing between practices'6; 
18; 141 is largely 
accounted for by differences in the needs of the patientS35-, 
46 
. Between European 
countries there is also variation cause by differences in regulation, marketing, and 
distribution of drugS48. Caution is needed in interpreting the results of studies on the 
appropriateness of prescribing when it is judged by the clinicians who are doing the 
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prescribing. Cockburn and Sabrina found that although patients brought expectations 
to the consultation regarding medication, the doctors' opinions about their 
expectations were the strongest determinants of prescribing 142 . It is difficult to see 
any justification for the wide variation in the level of prescribing of drugs noted in the 
British National Formulary to be 'less suitable for prescribin gv143 - Nor can there be 
rational reason for using excessive doses of thiazides in the treatment of 
hypertension"'. When doctors are asked why they prescribe drugs of doubtful 
value"', the reasons given are 
patient demand (perceived) 
use as a placebo 
opinion/experience over-riding evidence 
However doctors appear to be more aware of the pressure to prescribe than of the 
preference for self care"'. 
Evaluation of interventions in future would be more sensitive to the area where 
prescribing can and should change if prescriptions were linked to clinical need and 
assessed by evidence-based algorith MS17; 147 . 
Expert opinion would be a poor 
substitute. Two studied from Peru 148 and Pakistan 149 suggest that specialists may be 
less willing to accept practical restraints on "good" prescribing and less likely to follow 
guidelines based on their own recommendations than the doctors for whom the 
guidelines were intended. 
Cost 
A shift in prescribing drugs in the formulary would be expected to reduce overall 
costs because the average price of formulary drugs is lower than non-formulary 
drugs. High quality prescribing for asthma increases costs, but overall the results for 
the respiratory group in the South showed that the greatest saving occurred in 1995, 
the year when there was there was the largest swing towards the use of drugs in the 
formulary. This is probably because the shift from expensive inhalers to cheaper 
equivalents saved more money than the cost of any increase in the overall use of 
inhaled corticosteroids. 
Figure 11 shows the rule of halves for formulary drug costs, including the rate of 
increase in price being half that of non-formulary drugs. Many drugs in the formulary 
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are well established, off patent and listed by generic name, such as amoxicillin and 
ibuprofen, for which the need to recoup the cost of research and development has 
passed. 
The best estimate on cost effects comes from the South cohort where the data can 
be assessed over a longer period of time. Practices saved just under E50,000 in total 
during the January to March quarter over seven years between 1992 -1998 inclusive. 
However 57% of this was accounted for by savings on the prescription of antibiotics, 
with most of the rest of the saving being from the musculoskeletal group. To estimate 
the overall saving a correction must be made for the reduced requirement for anti- 
infective agents in the other quarters of the year. Correction factors have been 
published 150 , 
but they are ten years old and the factors were calculated from 
prescribing data 1983-1987. No factor was found necessary for the musculoskeletal 
group. Compared with the preceding quarter year, factors for preparations acting on 
systemic infections in Bedfordshire were: 
" January-March 8% 
" April-June -18% 
" July-September -9% 
" October-December 26% 
The factors refer to the number of items, not cost. They were not designed for 
sequential use, but simply to compare one quarter with the next in order that short 
duration audits could be done. All these difficulties mean it would be wise to err on 
the side on a conservative estimate of cost savings related to the formulary over the 
full years 1992 - 1998. Accepting the factors directly would suggest that for the 
infection group, a saving of El 00 in the first quarter of a year would result in a saving 
of about: E350 over the 12 months. I prefer to reduce the estimate, assuming aE 100 
saving in the first quarter would save E300 over a year. If this is applied to the South 
cohort data on costs, then the estimated saving would be: E1 17,000. 
In the North, total prescribing costs for the 9 subject practices were E13,000 lower 
than expected costs derived from controls in the first quarter of 1997, when only 4 
therapeutic groups had been considered, including two of those that showed savings: 
respiratory and musculoskeletal. Subject practices'costs were E27,000 lower in the 
first quarter of 1999, when all therapeutic groups had been discussed. Thus E40,000 
had been saved in just two quarters. Again, seasonal variations mean that it would 
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be inappropriate to assume this will be maintained throughout the year. The savings 
by the North cohort exceed those of the South, which saved: E27,000 in the first two 
January -March quarters, but such savings may not persist. The South cohort has 
reduced costs over a period of three years, but this may not happen in the North. 
The savings by the North cohort are less affected by seasonal variation than the 
South. Most of the savings were made in the respiratory, infection and 
musculoskeletal groups. Factors for preparations acting on the respiratory system 
are as follows: 
" January-March 1% 
" April-June -13% 
" July-September -1 % 
" October-December 12% 
However there is an 80% increase in the use of antihistamines in the spring, April- 
June, compared with the previous quarter. These drugs are included in the 
respiratory section of the British National and Bedfordshire Formularies. Applying the 
same conservative estimate to the infection savings, and using the factors above for 
the respiratory section, accepting the saving in musculoskeletal drugs as being 
consistent throughout the year, and ignoring other savings as being small in 
comparison, gives an estimate of: E1 18,000 saved in the two years of the North's 
formulary 1997 and 1998. 
The total estimated saving from both cohorts is: E235,000 over the seven years 1992- 
1998 inclusive. The grants to support all the formulary work totalled E40,000, which is 
17%. 
Who was affected 
It is no surprise that the delegates who helped develop the formulary were the 
doctors who changed prescribing the most. What is more interesting is that the 
partners changed more than the controls, as shown in Figure 12. This may be 
confounded by the problem that some practices have a repeat prescription policy 
which uses a duty doctor's prescription pad for all the repeat prescribing on 
the day 
that doctor is on duty. The prescribing data is attributed to the doctor's pad rather 
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than the signature. It is possible for a doctor who developed the formulary to be 
writing some prescriptions on partners' pads. This is not likely to be the whole 
explanation for the effect seen in Figure 12. Most repeat prescriptions would not be 
changed without seeing the patient, so no change would be reflected in the partners' 
data on this account. Many prescriptions are produced by computer, which 
automatically prints the correct doctor's details on the prescription 
There does seem to be a practice effect. Some practices are known to have had 
clinical review meetings, after one partner had been to a formulary meeting, in order 
to discuss the outcome of the meeting. This may have been encouraged by the 
feedback provided, which included information about the whole practice prescribing, 
not just the delegate's prescribing. More recently, since the end of the prescribing 
analysis in 1998, the formulary has been integrated into some practice computer 
systems. This would imply a general acceptance of the formulary amongst the 
partners. No estimate of the effect on partners has been made for the North cohort. 
It would be reasonable to conclude that not all partners need to contribute to a 
formulary actively for it to have an effect on the whole practice. 
Combining the formularies 
The acceptance by the North cohort of 72% of the South formulary would suggest 
that most new formularies could be started with a group of common, uncontroversial 
drugs. These are listed as the drugs without underlining in Appendix F. 
The focus group identified a further 7% of the differences as near matches, but also 
proposed new items in response to the inclusions in the North formulary which had 
not been considered by the South cohort. Many were new drugs or concerned new 
uses for older drugs. The result was a list of 95 items that needed to be considered, 
but 41 of these were simple decisions that did not rest on therapeutic information. It 
was possible to reach agreement on all the differences in one large evening meeting, 
functioning as five small groups of 15-20 people each. It was popular. Approximately 
70 doctors and nurses contributed and were interested and accepting of other small 
groups' decisions. Perhaps this will be how centralised guidance can be locally 
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owned, although there may be less scope for discussion and adjustment in some 
guidelines. 
Future formulary development 
Signposts 
The systematic review revealed that the three methods with the most evidence for 
influencing prescribing are: formulary development by prescribers, continuing 
professional education and feedback on prescribing. All three were used in the 
development of the primary care formularies in Bedfordshire, so it is in keeping with 
previous research that we find the intervention did affect prescribing. This does not 
mean that that developing a formulary is the best or only way to influence 
prescribing, because other methods may be quicker or cheaper. A systematic review 
of 102 trials of interventions to improve professional practice found no magic bullets 
but recommended a mixture of methodS56. 
The degree of influence of various methods has been assessed in a meta-analysis of 
26 studies conducted between 1979 -1991, which shows that methods targeted at 
the individual's needs work best 151 . 
There is evidence to support group work in this 
field over individual education 29 , and 
that education and contact with colleagues 
account for about half the changes that are initiated in practice 152 . 
We also know that 
doctors change their prescribing habits for a wide range of reason S153 . 
Horder, 
Bosanquet and Stocking's paper 154 on 'Ways of influencing the behaviour of general 
practitioners' can be summarised as follows: 
If a formulary is to be widely adopted, the participating GPs need to be sure that 
it is 
necessary. Personal contact with doctors, nurses, other colleagues, and to a 
lesser 
extent patients, is effective. Financial incentives and unsolicited feedback about 
performance is of doubtful efficacy. The most successful approach uses a 
combination of different methods. 
A decade later, the World Health Organisation, in its review of promoting rational 
prescribing, recommended using a wider variety of methods to influence change -14 
prescribing protocols 
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" consensus 
" feedback 
" face-to-face education 
" focused, structured forms 
" educational campaigns 
Future development of prescribing support is likely to take advantage of information 
technology. Some, but probably not all, visits from a drug educator or pharmacist 
could be replaced by distant support via the clinical desktop computer. The 
Bedfordshire Formulary CDROM offers advice in this way, but does not yet take full 
advantage of integration with the clinical system. Information appearing at a time 
when it is most relevant and most needed would be the aim. This would combine 
aspects of the method of problem-based learning, critical event education, personal 
reflection, with specialist support. It could answer the needs of GPs who prefer to use 
one or two sources of information for all questions relating to drugs, while satisfying 
the needs of those who prefer multiple sources by providing links to the relevant 
information, local or distance 155 . 
Such a method would powerfully combine many of 
the methods of influencing prescribing identified in the systematic review. 
Influence of the pharmaceutical industry 
Sponsorship by the pharmaceutical industry can weaken the message of 
independent drug information 128 . 
Many doctors continue to receive much of their 
continuing education on drugs directly or indirectly from companies that profit from 
increased prescribing of their prod UCtS48; 
156; 157. Information provided by 
representatives is generally accurate, but is a selection of evidence in support of a 
particular prodUCt158 . 
Although the industry follow guidelines agreed with the medical 
profession, promotion of high quality prescribing is difficult when the industry is 
98; 159-161 involved . 
Independent educators have successfully adopted some of the 
methods used by representatives to achieve a change in prescribing 
162 
. 
Attracting 
doctors away from the convenience of a visit by a company representative, who is 
offering free advice and other gifts, is a challenge for the future. Reaccreditation may 
encourage more doctors to seek independent information. If that information can 
be 
presented in a convenient way, doctors may be in a stronger position to challenge 
some of the bias in the information they receive from other sources. 
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Education or Information 
There has been a gradual shift in the terms used to describe methods of changing 
professional behaviour from passive absorption of information selected by a teacher, 
towards active learning by the student. 'Training' and 'post-graduate education' gave 
way to'continuing professional development' and 'life-long learning'. The problem 
with the newer terms is that they sound more like a burden than an opportunity. I see 
a further shift away from 'education' as the core to professional development towards 
terms that reflect the ability of practitioners to access information when and where it 
is needed. Learning has an association with memory, but with the huge body of 
knowledge available to those who seek it out, memory is not the key skill it once was. 
The challenge for the next batch of primary care formularies is to take over and 
improve upon the prescriber's memory by being more reliable, more knowledgeable, 
more up-to-date, and nearly as easy to access. 
Incentives 
Fundholding allowed practices control over money saved on drugs. This did limit the 
rise in costs of the fundholders in the early 1990s more than non-fundholders 163 , but 
the effect was modest, explaining less than 10% of the variation in cost per item and 
even less of the variation in total costs between practices. The uptake of fundholding 
was low in Bedfordshire and occurred at similar rates in the subject and control 
groups. 
Prescribing incentive schemes reward doctors for prescribing according to certain 
criteria. These schemes are mandatory for Primary Care Groups throughout England 
and Wales. While they do affect prescribing'O', the majority aim at limiting 
expenditure on drugs, rather than encouraging appropriate prescribing. 
Very few 
include clinical information on the needs of the patients. The development of 
Primary 
Care Trusts gives us the opportunity to link incentive schemes with clinical audit and 
governance to encourage and reward appropriate prescribing. The scheme 
in Luton 
this year includes a target based on the appropriate use of aspirin 
to prevent strokes 
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and infarcts 94 .A cheap, effective drug, with room for wider use 92 , it is seen as an 
innovative part of the incentive scheme, aiming to improve care for patients and not a 
need to save money on the drug bill. 
Doctors' knowledge of the cost of drugs 
Prescribing is influenced by the doctor's knowledge of the cost of the drug' 16 , 
but 
often that knowledge is either lacking or inaccurate' 64 . 
Only one third of estimates of 
cost by Scottish GPs were accurate to within 25%. Errors tended towards mean drug 
CoStS161. At a focus group discussion of GPs with a particular interest in prescribing, 
researchers and health economists, held at the department of health in June 2000, 
none of the 20 delegates knew of the differential cost of anti-viral drugs for shingles 
as mentioned in the formulary: 
"A shingles treatment pack of Valaciclovir costs E98.50, in sharp contrast to El 5.99 
for the equivalent pack of Aciclovir (of which it is a pro-drug). " 
There is a such a large body of information in constant flux that it is hardly surprising 
that doctors will not know when a product comes off patent, or that the maximum 
dose of a course of colchicine recommended by the British National Formulary has 
dropped by 40%, or that the costs of providing apornorphine in pre-filled syringes 
instead of ampoules would pay for a full-time personal nurse to give each injection 
166 
Lack of time to keep up-to-date with developments in therapeutics has been 
identified by GlPs as a major factor in explaining the variation in prescribing between 
practiceS45 . 
Formularies are seen an important solution to this, and one that is not as 
restrictive as some doctors imagine 167 . 
Automatically providing information on costs through a practice computer system 
may be a useful way to warn prescribers of an unusually high cost for an item 
compared with similar drugs in the same therapeutic group. This may not be 
welcomed by doctors with high prescribing costs, who are known to have more 
concern than their cost-conscious colleagues do over financial restraints' 
68 
. 
The 
article referenced puts forward the suggestion that high prescribers may be using 
prescriptions to cope with clinical workload and their perception of demanding 
patients. 
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Repeat prescribing 
The Bedfordshire Primary Care formulary offers guidance on selecting and initiating 
medication. It gives no advice on repeat prescribing policy. The only influence the 
formulary may have would occur when a doctor or nurse reviews the need for a 
repeat prescription. Yet Zermansky found that 66% of repeat drugs show no 
evidence of authorisation by a doctor; and 72% show no evidence of having been 
reviewed by a doctor in the previous 15 months. The problem is that it takes time to 
review medication; time that many GPs do not have available. Zermansky goes on to 
suggest imaginative use of nurses and pharmacists may help to solve this major 
problem. This adds more weight to continuing the formulary as a multi-professional 
tool. GPs have a positive attitude towards community pharmacists, their inclusion into 
the primary health care team and extension of their role in relation to medicines, but 
there is less support for the idea of pharmacists undertaking screening and running 
therapeutic monitoring clin iCS169. Where such roles for pharmacists do occur, they are 
usually to be found in large training practices 170 . 
The patient's view 
We had no patient representatives at the formulary discussion meetings, although 
professionals often discussed acceptability, the burden of taking medication, and 
tried out harmless products provided for this purpose at the meeting, such as 
creams, ointments, sprays and dressings. The difficulty with inviting the public is that 
this would affect the discussion among professionals. However, exclusion is not a 
good option either. Patients are affected by the decisions taken on prescribing. The 
chance that a person treated for depression with a selective serotonin re-uptake 
inhibitor will complete an adequate course is affect by restriction on the choice of 
drug 171 
.A 
formulary can save money at the expense of patient satisfaction, for 
example the substitution of lansoprazole for omeprazole 
172 
. 
Patients' view may have 
to be sought separately from the meetings on therapeutics. 
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Conclusion 
Main conclusion 
Practices can collaborate to create a shared formulary, which influences prescribing. 
Secondary conclusions 
Sharing resources between practices to create a primary care formulary can lead to 
modest changes in prescribing, sustained over three years, and lower overall costs. 
The largest observed changes were a 14% change in the choice of drugs for 
musculoskeletal conditions, and a saving of E5000 per practice per year on 
antibiotics. Such changes, attributed to the development of a formulary, also occur in 
practices that have no direct involvement, but later by three years. The greatest 
change in prescribing is seen immediately after a formulary is created and in those 
involved with its development. The funding for the work is estimated to amount to 
17% of the saving on prescribing. Doctors and nurses from 32 practices can work 
together on such an intervention. 
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Appendices 
Appendix A Bedfordshire Primary Care Formulary 
The formulary is provided on the CDROM to be found in the envelope bound with this 
thesis. It was last updated on 25 th April 2000. The latest version can be found at 
www. wlhc. demon. co. uk/formulary 
Three formats are available, as provided to practices. The easiest one to navigate is 
the HTML version. 
Directory Files Description 
Word Formulary The main formulary document 
files in this directory are 
suitable forprinting from 
Appendix A Details of items previously deleted 
from the formulary 
Microsoft Word Appendix B Forms to propose new items or 
exclude ones from the formulary 
Revision 170200 Changes made on 17 Feb 2000 
Read Me This document 
HTML index Start by clicking on this file 
files suitable for viewing in FORMUxxx Web pages of the main formulary 
a web browser or via the 
internet 
Other files Resources for the web site 
Wax / books / Formular 
files for loading into Wax 
Set of 4 Formular files Wax book 
A: \ 
text file in case you do not 
have Microsoft word 
Read Me This page in plain text 
The files can be accessed directly from the CDROM- Practices usually load the files 
on to the hard drive on a practice computer system, or have the formulary integrated 
into the clinical software program for the practice by one of the Primary Care Group 
pharmacists. So far this is only available for EMIS and Torex systems. 
104 
These are the instructions to practices: - 20 
To load files simply copy them from the CDROM to a suitable location on your hard 
disk. 
Typical locations: 
Word files in My Docurnents/Formulary/Word/ 
HTML in My Documents/FormularyNVebpages/ 
Wax copy the whole Formulary directory into Wax/books/ 
For quick access to the formulary you may like to put a shortcut icon on your desktop 
to either the word version "Formulary" file or the HTML version "index" file. To do this, 
first copy the files to your hard disk. Then locate the file you want to create a shortcut 
to by using Windows Explorer. Click with the right button on the file. On the drop 
down menu, click with the left button on "Create Shortcut". A new file will appear 
called "Shortcut to... " If you want to change the name to something shorter, press the 
function key F2 and type in whatever name you like, followed by return. Then make 
the Explorer window smaller by clicking on the middle of the three icons at the top 
right corner. Finally drag your newly created shortcut file to the desktop background. 
If this alters the pattern of icons on the desktop, you can line them up by clicking 
using the right button anywhere on the desktop and selecting "Line up icons". 
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Appendix B Proposal and Exclusion forms 
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Appendix B 
Bedfordshire Primary Care Formulary 
PROPOSAL FORM Your name & contact 
1. Date: 
2. Name of drug: 
3. Is this a proprietary name? 
I Do you wish to propose 
this brand only? 
I 
Or generic versions? 
No Yes 
4. Formulations proposed? 
All Some 
5. Does this item replace one in the formulary? 
No Yes E 
6. What is the main indication? 
Which formulations? 
Which item does it replace? 
Is it (tick any that apply): 
more effective 
safer 
easier to take F] 
better value EJ 
II 
7. Please comment on the reason for the proposal: 
8. Do you have any conflict of interest affecting this proposal'? 
No Yes What? 
Return to Lorraine Dakin, Wigmore Lane Health Centre, Luton LU2 8BG 
Bedfordshire Primary Care Formulary 
Fax 01582 456 259 
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Appendix B 
Bedfordshire Primary Care Formulary 
EXCLUSION FORM Your name& contact 
If a drug is to be replace by a newly proposed drug, use the DRUG PROPOSAL FORM 
............................. ' ...... ... * ............................................... 
1. Date: 
2. Name of drug: 
II 
3. Formulations excluded (tick one): 
List those to be excluded 
All Some L 
4. Reason for exclusion (tick as many as apply): 
Ineffective Duplication 
1 
110. 
With what? 
What side-effects? 
Rarely Unacceptable 
required side-effects 
Poor value Unacceptable 
to patients 
5. Please comment on the reason for the exclusion: 
Why? 
6. Do you have any conflict of interest affecting this exclusion? 
No Yes 
I T-* I What? 
Return to Lorraine Dakin, Wigmore Lane Health Centre, Luton LU2 db(3- Fax ui obz 4z)t) zotp 
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Dr Anonymous 
Jan-March 1991 In No of Rx Jan-March 1992 In No of Rx 
Ventolin Inh y 49 Ventolin Inh y 43 
Becotide N 35 Bendrofluazide y 39 
Sudafed N 29 Atenolol y 33 
Bendrofluazide y 28 lbuprofen y 29 
Atenolol y 27 Terbutaline inh, turbo y 25 
Co-Amilozide N 20 Nifedipine y 22 
Ventolin N 20 Becotide N 22 
Nifedipine y 17 Frumil y 19 
Tiaprofenic Acid N 15 Pseudoephed HCL y 18 
Frumil y 14 Budesonide inh, turbo y 16 
Jan-March 1991 In E Jan-March 1992 In C 
Becotide N 575.89 Nifedipine Y 541.83 
Tiaprofenic Acid N 334.16 Becotide N 487.86 
Atenolol Y 321.14 Atenolol Y 388.23 
Nifedipine Y 311.02 Captopril N 357.24 
Captopril N 226.78 Budesonide inh, turbo Y 315.50 
Ventolin N 225.00 Terbutaline inh, turbo Y 205.25 
Ventolin Inh Y 212.22 Ventolin Inh Y 201.74 
Fenbufen N 206.99 Tiaprofenic Acid N 196.36 
Frumil Y 137.84 Ventolin N 183.10 
Pulmicort N 131 . 00 
Ketoprofen Y 174.00 
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Table of cost implications 
This table shows the effect of the formulary on the cost of prescriptions Jan-March 93 
The second column shows the expected cost if the proportion of presciptions for 
drugs in the formulary before the meetings had been continued into 1993. Subtracting 
the actual cost gives the saving. Negatives value represent an increased in cost. 
DrX 
BINIF Group Expected Actual Saving 
I (Gut) 3873 3875 -2 
2 (CVS) 9116 8116 1000 
3 (IRS) 5731 5852 -121 
4 (CNS) 4154 4143 111 
5 (AntiB) 3310 3898 -588 
6 (Endo) 1491 1375 116 
7 (Obs/G) 1240 1245 -5 
9 (Nut/Bid) 476 494 -18 
1 O(MSk) 4439 3943 496 
All 33829 32941 888 
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Appendix D Measuring changes in pilmary care prescribing - 
traps for the unwary and how to avoid them 
This paper has been submitted to the British Journal of General Practice. 
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Measuring changes in primary care prescribing - traps 
for the unwary and how to avoid them 
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Summary 
The principles of how to use and interpret prescribing data are readily available from the 
Prescription Pricing Authority, but there are many traps in converting the principles into 
practice. Described here is a simple tool to assess prescribing. It removes the effects of 
many confounding variables. It may be helpful to anyone wishing to assess the impact of 
local initiatives on prescribing in primary care. 
Introduction 
Now that Primary Care Groups are responsible for drug budgets, many more people 
across the United Kingdom will be involved in analysis of prescribing. Of particular 
importance is the strong link between the clinical governance agenda to improve quality ZD 
and the new ability of primary care group prescribing advisors to support good 
prescribing practice. Interventions to improve prescribing are often evaluated using data 
from the Prescribing Analysis and Cost (PACT) data 1 (PPD in Scotland), but the sheer 
volume of data and the complexity of the activity underlying the figures mean that it is no 
easy task to reach firm conclusions. Standard analysis can be done using the electronic 
version online ePACT, although access is restricted to preserve confidentiality. 
This article addresses problems that face anyone trying to answer a specific non-standard 
question using primary care prescribing data, and presents a method which enables the 
effect of an intervention to be assessed while minimising the effect of confounding 
variables. Standard methods are often designed for national or research covering a 
large 
area, but local initiatives in primary care, such as the evaluation of a 
formulary or 
educational programme, require analysis of prescribing relating more specifically 
to the 
intervention. Some of the pitfalls are well known, some more obscure. Whilst it is not 
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possible to offer a complete solution for each one, being aware of the difficulty is half the 
battle. More realistic conclusions can be reached once it is appreciated that they rely on 
certain assumptions, which will not always be valid. Small or moderate changes resulting 
from interventions to improve prescribing need to be carefully extracted from substantial 
2,3 background variation, intrinsic to prescribing data 
As a general example, assume we wish to evaluate the effect of an intervention to 
improve prescribing. It may be a prescribing incentive scheme, or a new formulary, or a 
series of practice visits by a pharmacist, or anything that happens to some practices within 
a given time. The type of parameters of interest include volume of prescribing, choice of 
drug, and cost. 
The Difficulties 
1. What are we counting? 
The item can be any size. 
A prescriptionfor one item can be anythingfrom a single tablet to a six month supply. 
The difficulties in using such a variable unit have been the subject of entire paperS4 - 
Defined daily doses offer an alternative 5,1. The choice depends on the question being 
asked. If volume ofprescribing and cost analysis are central to the study, 
defined daily 
doses may be better; if it is the activity ofprescribing that is central, the choice of 
drug, 
the decision to prescribe, rather than how much, then the item may 
be a more appropriate 
unit. 
List size. 
Notoriousfor causing difficultieS7 . This is the 
denominatorfor all thefractions often 
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quoted where a parameter is expressed relative to the list size of a practice. Rather than 
simply using the number ofpatients, aformula to calculate prescribing units (PUs I or 
ASTROPUs' or STARPUs'O) is usually used in an attempt to compensatefor thefact that 
certain groups ofpatients require more medication than others. Despite these 
improvements, list size remains one of the biggest jokers in the data pack. Prescribing is 
not simply related to the number ofpatients in a linear way, but influenced by the demand 
for treatment, and the availability of doctors to prescribe. A partner retiring and not 
being replacedfor several months could have a major impact on prescribing despite a 
steady list size. Such events happen often enough to disrupt studies involving a small 
sample ofpractices. Bizarre swings in the supposed prescribing are usuallyfound to be 
an artefact of a sudden change in list size. such as a practice taking over the list of a 
closing practice. 
2. Collecting the data. 
Access to PACT data is restricted. 
Unless you have implied consent by virtue of your post as an NHS prescribing advisor or 
researcher, full detail PACT data are only available with signed consent of all partners 
in 
a practice. This applies to GP board members of Primary Care Groups, even though they 
are subcommittees of Health Authorities and accountable for the drug 
budget. In fact, 
veryfew practices withhold consent. Between 1991 - 1998 1 analysed 
PACT data to 
assess the impact of developing a primary careformulary 
for Bedfordshire, withfull 
signed consentfrom all doctors in 20 practices. PACT 
data were delivered in boxesfull of 
paper, requiring painstaking effort to re-enter the data on to a computer 
database so that 
it could be analysed. The development of ePACT and the possibility 
to download this 
information is most welcome. There may be difficulties in permitting access to a non- 
standard set of data.. such as only 20 out of 
100 practices spread across the county. 
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It is not time to question the assumption that doctors want tight security about this 
information, particularly as it concerns public money? 
PACT data changes occasionally 
In 1994, list sizes were included in thefull catalogue PACT data, what was then called 
level-3 data, butfrom 1995 onwards they only appeared in the summary level-]. 
Unexpectedly, signed consentfor level-3 data did not entitle a researcher to the simpler 
level-] printout. This disappearance of the list sizze halted research until a complete new 
set of signature could be obtained. More recently the way in which the proportion of 
generic items is calculated was changed to exclude dressings ". Vigilance is needed to 
spot these changes, otherwise there can be an unexplained shift in prescribing or a big 
hole in the data. 
3. Finding the ripple of evidence amongst the ocean waves. 
Wide variation in prescyibing between practices. 
Simple comparisons between small groups ofpractices using average levels of 
prescribing will be unlikely to detect the effect of the intervention, even if there is one. 
The inter-practice variation will mask differences in prescribing caused by the 
intervention. The standard PACT summary compares a practice with a Health 
Authority 
or National equivalent practice, an imaginary practice with the same number of 
prescribing units. This is an unmatched comparison. Two practices with the same number 
ofprescribing units may have quite different prescribing to meet the needs of 
their 
population ofpatients. The standard statistical method to 
deal with this problem is to use 
matched pairs of subiect and control practices12 , 
but well-matched practices are difficult 
tofind. A compromise which goes some way towards this ideal 
is to apply shifts in the 
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demand, as seen in other nearby practices, for prescribing of a particular drug or small 
therapeutic groups of medication (eg 3 commonly used beta-blockers, 2 particular 
antihistamines). Then an imaginary practice can be created by applying these demand 
factors to the actual prescribing of a real subject practice in year I to predict how that 
practice would prescribe in year 2 in response to local demands. Such an imaginary 
practice is a better match for the subject practice than a Health Authority or National 
equivalent practice. 
Seasonal variation. 
This invalidates any study which looks at prescribing immediately before and after an 
intervention, when prescribing levels in different months may be wildly different, 
particularly in the case of antibiotics. Attempts have been made to allow such 
comparisons 13, by applying average adjustments to compensatefor the seasonal 
variation, but such adjustments cannot take into account local epidemics, media releases, 
new drugs or newly discovered problems with old ones. Furthermore, the source of these 
adjustmentfactors is now 10 years old. 
Price changes are unpredictable. 
The price of a particular drug can change suddenly as a result of marketforces or 
Government price negotiation. Even the average price of drugs cannot be expected to 
follow the general inflation rate of any one country 14 . 
Individual doctor's data are unreliable when prescribing is a team activity 
List size problems are amplified when it comes to looking at the prescribing of a single 
doctor. Junior partners will often have small lists but actually prescribe 
for a full 
partners'share of the patients in a practice. Computerised repeat prescriptions 
do not 
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always bear the name of the responsible doctor. Locums, registrars and deputising 
services confuse the picturejurther. Unless a practice operates a strict individual list 
system which also includes aformal repeat prescription policy, analysis of an individual 
doctor's prescribing cannot reliably reflect that doctor's prescribing. 
4. Mathematical pitfalls. 
Absolute proportions are invalid. 
For example, if a control practice increases a proportion parameter, such as generic 
prescribing, by 17%, it would be invalid to expect a subject practice to change by 17%. 
The control practice might have shiftedfrom 40% to 57%, whereas if the subject practice 
were already at 86% it could hardly increase to 103%. More on this later. 
Regression towards the mean ". 
Primary Care Groups may target practices where prescribing is unusual, the outliers on 
the bar charts. After an intervention, a shift towards the mean could easily be 
misinterpreted as a sign that the intervention had an effect, but injact such a shift would 
be expectedfrom the natural tendency of a sample of outliers to become more average. 
This is a statistical, not a prescribing phenomenon. 
5. Interpreting the data. 
PACT is amalgamated data unlinked to either the patient or their illness. 
Quality ofprescribing cannot be assessed by using PACT data alone16,17 exceptfor 
drugs with high risk to benefit ratio which should not be prescribed at all. 
Lack of validated prescribing indicators for primary care. 
Indicators that are used in general practice are based on opinion as to what should 
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represent good prescribing 18,19. Even the best known of these, the brown to blue 
(corticosteroid : bronchodilator) ratio of inhalersfor asthma has been shown to be 
unreliable in assessing quality ofprescribing 20,21. What we need are evidence-based 
indicators, such as those used in secondary care". 
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A Suggested Method 
General principles 
Aim to apply standard principles of research to any study on prescribing. Units have to be 
defined and used consistently throughout, even if they are not perfect in themselves. On a 
shifting background, a control group is essential. Comparisons have to be made between 
groups that are as closely matched as possible, so use the same months of the year and the 
same practices. A decision has to be made about what represents the smallest unit in the 
sample, is it a doctor, a practice, a Primary Care Group, or a still larger group? The 
smaller the unit the bigger the apparent sample size, but also the bigger the natural 
variation in the data for each unit. Analysis by practice is usually a good balance. 
A compromise which goes some way towards the ideal of using matched practices as 
controls is to apply shifts in the demand for medication, as seen in other nearby practices, 
to prescribing of a particular drug or small therapeutic groups of medication (eg 3 
commonly used beta-blockers, 2 particular antihistamines). Then an imaginary practice 
can be created by applying these demand factors to the actual prescribing of a real subject 
practice in one year, to predict how that practice would prescribe the following year, 
in 
response to local demands. Such an imaginary practice is a better match 
for the subject 
practice than a Health Authority or National equivalent practice. At 
first sight, it may 
seem that the two methods are the same. The reason for the 
difference and slight 
improvement in matching is the application of demand factors to small therapeutic groups 
before totalling, instead of an averaged demand factor applied to total prescribing in a tý 
larger therapeutic group. For example, the number of items of three small therapeutic 
groups of drugs prescribed by a subject practice January-March 
1999 is A, B and C. Other 
nearby practices show that demand for prescribing changes thus: 
A changed by a factor 
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dA, B changed by dB, and C changed by a factor dc. Mostly these demand factors are in the 
range 0.9 - 1.1. After an intervention in September 1999, we wish to see if the subject 
practice is prescribing differently in January-March 2000. A Health Authority equivalent 
practice as shown on a PACT standard report would give an expected level of prescribing 
of (A+B+C) multiplied by the average change in demand (dA+dB+dc)13. This is does not 
give the same result as applying the demand factors individually before totally, which 
would be (A. dA+B. dB+C. dc). This result more closely matches what the subject would 
have prescribed without the intervention because it takes into account the levels of 
prescribing of the small therapeutic groups, reflecting the population needs that practice is 
serving. 
The rest of this article describes a method which overcomes some of the difficulties 
outlined above. The mathematical pitfalls are avoided, the inter-practice variation and 
powerful external influences are accommodated, and the list size problem disappears in 
the section 2. 
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A Suggested Method 
Visualising the comparison with vectors 
The term is borrowed from mechanics, where two independent forces can be analysed to 
find out the direction and strength of the combined force. When applied to prescribing, 
one force is the effect of an intervention and the other is the effect of every other 
influence. The aim is to enable a comparison of a practice (or group of practices) before 
and after an intervention. In order to do this we need to minimize the effect of the many 
external influences. To see the effect of the intervention, we need to look at the difference 
between the practice prescribing after the intervention and what it would have been if the 
intervention had not happened. 
A dinghy that hoists a sail will end up in a different place to one that drifts with the tide. 
The difference in the final positions is the effect of the sail. See Figure 1. 
To estimate how practices would have prescribed without intervention, the following 
information is needed: 
1. the initial prescribing of the practices before the intervention, equivalent to 
the starting position of the dinghy 
the external influences on presciibing: 
a) the list size factor, which adjusts for changes in the number of people 
registered with the practices 
b) the demand factor, which adjusts for changes in the need for 
prescriptions for a group of drugs 
These external influences are equivalent to the tide in the marine analogy. 
The factors are 
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derived from control data from a large number of practices in the same locality. Suitable 
control data can be obtained by subtracting all subject practices' data from county or 
Primary Care Group data, leaving amalgamated data on all practices not involved in an 
intervention. With these three pieces of information, an expected value can be calculated 
for the practices, which can be compared with the observed value using standard 
statistical tests, in order to measure the effect of the intervention. 
Calculating the vectors 
Simple arithmetic using nothing more than +-x -- is all that is required, but the method 
described below carefully avoids the pitfall which arises from summing proportions. For 
example, the correct way to apply control data to a practice's initial prescribing in order to 
estimate what change in generic prescribing would have occurred without intervention, is 
to calculate the effect on generic and non-generic prescribing separately and then find the 
predicted proportion of generic prescribing. Following the method given will ensure such 
calculations are done in the right order. 
Parameters of prescribing 
The method gives information on three aspects of prescribing: volume, choice of drug, 
and cost. It is independent of the units used, but the units must be the same throughout. 
For simplicity, I refer to items as the unit of prescribing. The most reliable measure of the 
impact of an intervention is when the choice of drug is influenced. This is because it is 
independent of list size. The way to assess it is given in section 2. 
Maximising the power of the method 
Results will be more reliable if the control data is a good match 
for the subject data, for 
example if all the data used applies to the same group of 
drugs. If the aim is to measure 
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the impact of a pharmacist visiting practices to discuss drugs for musculoskeletal 
conditions, those in chapter 10 of the British National Formulary, then the control data 
should apply to exactly the same group of drugs. For overall assessment of the influence 
of an intervention on cost, it is best to analyse groups of drugs separately and add together 
the cost changes afterwards. Amalgamating the data first would result in a poorer match 
between the control and subject data. For example, a general inflation in the cost of 
certain expensive cardiovascular drugs should not be allowed to mask a significant 
change in the prescribing of analgesics just because they are cheaper. In fact the smaller 
the group of drugs analysed, the more powerful the method, but the price to pay for this is 
the need to subdivide the prescribing data down to individual drug level. There must be a 
limit to focusing down on a very small group of drugs, especially rarely used ones, 
beyond which the number of items prescribed in the time studied becomes low enough to 
impair the statistical power. Pragmatically the usual limitation is not the number of items 
prescribed but the number of practices in the sample. A formal estimation of the number 
of practices required to represent a sample size sufficient to detect a certain degree of 
change requires knowledge of historical variability in local prescribing. This data is held 
by Health Authority pharmaceutical advisors. In my experience, a sample of ten practices, 
such as might be found within smaller primary care group areas, will be sensitive to 
changes in prescribing over about 5 %23. 
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Vectors applied to prescribing 
The idea of drawing the vectors is simply to make the method that follows easier to 
visualise. Each parameter of prescribing activity can be plotted vertically against time 
horizontally. See Figure 2. 
To simplify the calculations and avoid the problems of seasonal variations, we can keep 
the right hand vector vertical by finding the expected prescribing for the same time period 
for which we have data about actual prescribing. The next section gives the method of 
finding the position of the expected prescribing point for each of three parameters: 
volume, choice of drug and cost. Subtracting the expected from the observed point gives 
the estimated influence of the intervention. 
Finally, a worked example using real data is included. 
1. Influence on the volume of prescribing 
for example, number of items per quarter year. 
1. Factor 1. Change in list size (more patients will require more prescriptions) 
lsf. list size factor for subject s 
lsý, list size of subject in Year y, using the same date in each year 
(year 0 is prior to the intervention) 
ls-9 ( 
lsf. = 
lss(O) 
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2. Factor 2. Change in the demand for prescriptions 
Change in demand is estimated by change in the frequency of prescribing, for example an 
epidemic increasing antibiotic prescribing. 
df, ý demand factor calculated from control group's data 
ic (Y) number of items prescribed by control group in a quarter of year y 
ic(y) / lsc(y) 
dfc 
ic(o) / isc(o) 
3. The expected volume of prescribing of a subject can be found using the factors 
is (Y) observed number of items prescribed by subject in a quarter of year y 
expected is (y) is(O) . lsfs . dfc 
This is the volume prescribed at baseline, adjusted for changes in list sizes and demand. 
This can be compared with the observed volume of prescribing of the subject in a quarter 
of year y. The difference between the observed and expected volume of prescribing is the 
intervention vector. 
Statistical tests: 
1. mean and confidence intervals can be calculated for the changes in volume of 
prescribing by a group of su. . ects 
2. p values can be calculated by using matched paired t-tests, with each pair 
being 
observed is(y), expected is(y). This is arobust test which 
is valid if the 
sample data is drawn from a population which is approximately normally 
distributed. 
3. Wilcoxon matched-pairs signed-rank test can be used to test a null hypothesis that the 
subject practices changed randomly, but this in itself gives no 
indication as to the degree 
of change. 
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2. Influence on the choice between drugs in and drugs out 
of a formulary 
A formulary could be any list of drugs within an intervention 
programme aimed at changing prescribing. 
1. Defining proportions. 
In a quarter of year y: 
p_ln,, (y) proportion of items prescribed by subject s which are in the formulary 
1_ins (y) number of items prescribed by subject s which are in the formulary 
i-Out. (Y) number of items prescribed by subject s which are outside the formulary 
1- ins (y) i_ins (y) 
p_ins (y) --------- - ----------------- - 
is (Y) i_ins (y) + i_out. (y) 
2. Expected volumes in and out of the formulary. 
Expected levels of prescribing of drugs in the fonnulary can be calculated by using the 
equation on volume: 
df 
-in,: 
demand factor for drugs in the formulary (calculatedfrom control data) 
expected i-in. (y) i-in,, (O) . lsfs . df_inc 
This is the number of formulary items prescribed at baseline, adjusted for change 
in list 
sizes and demand. 
Similarly, for drugs outside the formulary: 
df-out, ý demand 
factor for drugs out of the formulary (calculatedfrom control data) 
expected i-outs (y) i-out,, (O) . 
lsf. . df-outc 
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3. Expected proportions 
The expected proportion of items prescribed by subject s which are in the formulary 
expected p_ins (y) = 
(i_iný, (0) lsfdf_in, ) 
---------------------------- 
(i_in, (0) - lsf df_in. ) + (i_outs (0) - lsf df-outc) 
which simplifies to: 
(i-in., 
(i_in., (0) . df_in) 
. 
(i_out(0) . df-outc) 
(The list size factor cancels out because it affects the prescribing of drugs in and outside 
theformulary equally, and thus has no influence on the proportion. ) 
This can be compared with the observed proportion p_in., (y). See statistical methods in 
section 1 on volume above. 
Influence of the formulary on the choice between two drugs which are either both 
in the 
formulary, or both outside it, will not be reflected in this comparison. However, 
if there is 
a great difference in the cost of the two alternative drugs, then 
it would be possible for the 
formulary to influence prescribing costs without any apparent change in either volume of 
prescribing, or the proportion of drugs prescribed from within the 
formulary. 
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3. Influence on the cost of prescribing 
(this will depend on changes both in the volume ofprescribing and the 
choice of drug) 
1. Expected cost of prescribing by a subject s. 
In a quarter of year y: 
CS (Y) total cost of items prescribed by subject s 
c_ln,, (y) cost of items prescribed by subject s which are in the formulary 
C-Outs (Y) cost of items prescribed by subject s which are outside the formulary 
For drugs in the formulary, the expected costs can be calculated by multiplying the 
average cost of formulary items 
expected c-in,, (y) = expected i_in,, (y) . c-in, (y) 
iifls(Y) 
Similarly, for drugs outside the formulary: 
expected c-out., (y) = expected i-out., (y) . c-out,, (y) 
i-outs 
2. Expected total costs 
expected c., (y) 
expected c., (y) 
Total expected cost of items prescribed by subject s 
= expected c-in,, (y) + expected c-out, 
(y) 
This is simply the sum of costs for items in and out of the formulary. 
It can be compared 
with the observed cost of items prescribed in a quarter of year y 
by subject s. If the 
observed costs are lower than expected, then the 
intervention reduced costs. 
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2. What happens with the sail up 
3. Working out the effect of the sail 
Figure 1. Marine analogy 
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Prescribing 
Parameter 
Time 
Figure 2. Prescribing vectors 
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year(O) intervention year(y) 
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Worked Example 
In 1997, the dermatology section of a primary care drug formulary was developed in one 
part of Bedfordshirerof. It was distributed on New Year's Day 1998 to nine participating 
practices. To measure the effect of one chapter in the formulary, we will compare PACT 
data level-3 for the first quartet of 1996 with the same quarter in 1997. The example data 
(Table 1) refers to one of the nine practice's prescribing of drugs in chapter thirteen of the 
BNF, the dermatology section. The control data is obtained by subtracting the nine 
practices from the amalgamated data for the whole county. The units are: items 
prescribed, cost in E, and the prescribing list sizes in prescribing units as specified in the 
PACT level-1 data. 
1. Influence on volume 
List size factor 
lsf. = ls, (98)/lss(97) = 5047/4929 = 1.024 
Demand factor 
dfc =[ iI (98) 11sc (98) ]/[ ic (97) 11sc (97) ] 
= [77372/642632] / [76350/638720] = 
Expected volume of prescribing in 1998 
expected is(98) = is(97) . isf,, 
dfc! 
= 602 . 1.023 
1.007 620 
Actual number of items prescribed in 1998 
actual i. (98) = 572 
1.007 
Intervention caused a change in volume of prescribing of: 
572 - 620 = -48 
(The negative value means volume decreased) 
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Significance 
To find out if the subject practices changed significantly, calculate the changefor each of 
the nine practices. The data for the other eight practices are not included in the above 
example but give the mean of the differences between actual and expect prescribing 
volumes as +24.4 items, with a standard deviation of 82.7. For a sample size of 9, the 
95 % confidence interval is 24.4 +/- 68. This includes zero (no difference between actual 
and expected) and is not significant. Matched-paired t-test gives t=0.89, well below 
significance level. 
2. Influence on the choice of drug. 
Proportion of items prescribed by the subject practice in 1998 which were in the 
formulary 
p_in. (98) = 265/572 = 0.463 
Demand factor for drugs in the formulary 
df_in, =[ i_in,, (98) Ils,,, (98) ]/[ i_in,, (97) 11sc (97) 
= [35442/642632] / [34295/638720] = 1.027 
Similarly, demand factor for drugs outside the formulary 
df_out,,, = [i_out, ý(98)/lsc, (98)1 
/ [i_out, (97)/ls,, (97) ] 
= [41930/642632] / [42055/6387201 = 
0.991 
Expected number of items prescribed by the subject practice 
in 1998 which would be 
in the formulary 
expected i_in,,, (98) i-in,, (97) . 
isfs . df_inc 
246 . 1.024 . 
1.027 259 
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Similarly, for drugs outside the formulary: 
expected i-out,, (98) i-outs(97) 
. 
356 . 1.024 
lsfs . df-out, 
0.991 361 
Expected proportion of items prescribed by the subject practice in 1998 in the 
formulary 
259 
expected p_in,, (98) 
259 + 361 
= 0.418 
Intervention caused a swing towards the use of drugs in the fon-nulary of: 
0.463-0.418 = 0.045 
In other words, a 4.5% swing. Significance for the sample of subject practices can be 
determined in the same way as in section 1. Calculating the above for each of the nine 
practices gives a mean swing of 3.1 % with a standard deviation of 4.2 %. The 95 % 
confidence interval would be 3.1% 1/- 3.4%. This just includes the zero, so on the 
confidence interval one could not claim significance at the 5% level. The power of the 
statistical test can be improved by pairing each practice's actual and expected proportions. 
A matched-pair t-test gives t=2.2 1, which reaches 5% significance for a one-tailed test. 
The one-tail is appropriate for testing the hypothesis that the intervention increased the 
prescribing of formulary drugs. It is unlikely that developing a formulary would decrease 
the use of the drugs selected for inclusion by the participating practices, so the hypothesis 
that the intervention changed the prescribing choices, which would require a two-tailed 
test, is less appropriate. 
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3. Influence on cost. 
Expected cost of items prescribed by the subject practice in 1998 which were in the 
formulary 
expected c-in,, (98) = [expected i-in,, (98). c_in,, (98)]/i_in,, (98) 
= [259 . 1054] / 265 
= : C1030 
Similarly, expected costs for drugs outside the formulary: 
expected c-out., (98)= [expected i-out,, (98). c_out,, (98)]/i_out,, (98) 
= [361 . 2999] / 307 
: C352 7 
Expected total cost for all items in 1998 
expected cs(98) = expected c-in,. (98) + expected c-out,. (98) 
1030 + 3527 : C4557 
This can be compared with the actual cost of items prescribed 
: C4053 - E4557 = -: C504 
(The negative value means costs were reduced by the intervention) 
Remember this represents the saving by one practice, for items in one chapter of the 
BNF 
over one quarter year. The overall effect on cost can 
be found by totalling the change in 
cost for each of the nine subject practices. 
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Subject practice Control 
1997 1998 1997 1998 
Prescribing list size 4929 5047 638720 642632 
Items prescribed 602 572 76350 77372 
.. of which in formulary 246 265 34295 35442 Cost of items 4439 4053 396242 404288 
.. of which in formulary 1016 1054 122574 131201 
Table 1. Example data. Prescribing of dermatology items by one 
practice and a large control group 1997 - 1998. 
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Appendix E Sharing resources to create a district drug formulary 
a countywide controlled trial 
This is a reprint of a paper published in the British Journal of General Practice 
in 1996 as a report on the evaluation of the formulary in South Bedfordshire. 
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Primary Care Drug Formulary 
Comparison of North and South Bedfordsire 
North 
, 
Group 1 Gastro-intestinal 
Magnesium Trisilicate 
Gaviscon and Infant Gaviscon 
Infacol 
1.2 Mebeverine 
Dicyclomine 
1.3 Cimetidine 
South 
Magnesium Trisilicate 
Gaviscon 
Mebeverine 
Dicyclomine 
Cimetidine 
Ranitidine 
Nizatidine Nizatidine 
Lans9prazole 
1.4 Loperamide ! Loperamide 
Codeine Phosphate 
1.5 Sulphasalazine 
Mesalazine 
1.6 Fybogel Tybogel 
Regulan 
Bisacodyl I Bisacodyl 
Co-danthrusate 
rol 
Senna iSenna 
Manevac 
Lactulose Lactulose 
Micolette 
1.7 Anusol and Anusol HC jAnusol 
Betnovate 
Xyloproct Xyloproct 
Group 2 Cardiovascular 
Digoxin 2.1 Digoxin 
2.2 Bendrofluazide Bendrofluazide 
Frusemide Frusemide 
Bumetanide i jAmiloride Amiloride 1ýco-amilofruse Co-amilofruse i 
Propanolol 
2.4 Propanolol Atenolol Atenolol 
enoret 50 T 
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Primary Care Drug Formulary 
Comparison of North and South Bedfordsire 
North 
2.5 Doxazosin 
Enakp 
Lisinopril 
2.6 Glyceryl trinitrate 
Isosorbide MN 
Amiodipin 
Diltiazem 
Nifedipine 
i Adalat LA 
12.8 Warfarin 
ý2.9 Aspirin 
2.11 Tranexamic Acid 
2.12 
_Bezafibrate Simvastatin 
Group 3 Respiratory 
3.1 Salbutarnol 
including Ventolin Easi-Breathe 
Diskhaler 
volurnatic 
Terbutaline 
Nebuhaler 
Salmeterof 
1pratropiurn Bromide 
SIO 
Peak Flow Meter 
3.2 Beclornethasone 
including Beclazone 
Budesonide 
(6.4) Prednisolone 
3.3 Sodium Cromoglycate 
Spinhaler 
Insufflato 
South 
Lisinopril 
Glyceryl trinitrate 
Isosorbide MN 
Diltiazern 
Nifedipine 
Ada I at LA and Adalat Retard 
Wa rfa ri n 
Aspirin 
Tranexamic Acid 
Bezalip-mono 
Simvastatin 
Salbutamol 
Diskhaler 
Volumatic 
Rotahater 
Terbutaline 
Nebuhaler 
lpratropium Bromide 
Unoh 
Peak Flow Meter 
Beclomethasone 
Budesonide 
Prednisolone 
Sodium Cromoglycate 
Spinhaler 
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Comparison of North and South Bedfordsire 
North 
3.4 Terfenadine 
Loratidine 
Cetirizine 
Brompheniramine 
Chlorpheniramine 
7erfenadine 
Loratidine 
Haloperidol 
Thioridazine 
Chlorpheni ra mine 
3.6 
3.8 Menthol & Eucalvptus 
3.9 Simple Linctus 
Phokodine 
Simple linctus 
Pseudoephedrine 
Group 4 Nervous 
4.1 Temazepam 
Zopiclone 
Diazepam 
Temazepam 
Diazepam 
4.2 
-Chlo! 
promazine 
Thioridazine 
Sulpiride 
Lithium 
4.3 Amitriptyline 
Dothiepin 
Lofepramine 
Fluoxetine 
Citalp p 
Sertraline 
4.6 Metoclopramide 
Prochlorperazine 
including 
-Succastem Domperidone 
Cinnarizine 
4.7 Aspirin 
Paracetamol 
Co-codamol 8/500 
Co-proxamol 
Co-dydramol 
Codeine 
Dihydrocodeine 
Amitriptyline 
Dothiepin 
Lofepramine 
ClomOramine 
Fluoxetine 
Flu xol 
., 
penthi 
Metoclopramide 
Prochlorperazine 
Domperidone 
Betahistine 
Aspirin 
Paracetamol 
Co-codamol 
Co-proxamol 
Co-dydramol 
South 
8/500 & 301500 
Dihydrocodeine 
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Primary Care Drug Formulary 
Comparison of North and South Bedfordsire 
North 
4.7 cont. 
Morphine 
Pizotifen 
4.8 Carbamg"e in 
Sodium valproate 
Phenyto 
4.9 Co-beneldopa 
Co-careldo, pa 
Procyclidine 
4.10 Methadone 
Group 5 Infection 
5.1 Phenoxymethylpenicillin 
Flucloxacillin 
Amoxycillin 
Co-amoxiclav 
Cephalexin 
Oxytetracycline 
Doxycycline 
Minocycline 
Erythromycin 
Clarithromycin 
Trimethoprim 
Metronidazole 
N it rofu ra nto in plain & MR 
5.2 Nystatin 
Terbinafine 
Fluconazole 
5.3 Aciclovir 
5.5 Mebendazole 
Piperazine 
South 
Diamar phine 
Morphine 
Pizotifen 
Paramay 
Tegretol 
Sodium Valproate 
Madopar 
Procyclidine 
Phenoxymethyl penici II in 
Flucloxacillin 
Arnoxycillin 
Co-fluaMpicil 
co-arnoxiclav 
Cephalexin 
Oxytetracycline 
Doxycycline 
Erythromycin 
Clarithromycin 
Trimethoprim 
Metronidazole 
Nitrofurantoin MR 
Ciprofloxacin 
Nystatin 
Miconazole 
Fluconazole 
Valaciclovir 
Mebendazole 
Primary Care Drug Formulary 
Comparison of North and South Bedfordsire 
North 
Group 6 Endocrine 
6.1 Insulin 
i Tolbutamide 
Glibenclamide 
Gliclazide 
Metformin 
Glucago 
6.2 Thyroxine 
Carbimazole 
6.3 Dexamethasone 
6.4 Premarin 
PrQgyno 
Evorel 
Estraderm MX 
Prempak-C 
Climagest 
Kliofem 
Premýqu 
Norethisterone 
Dydrogesterone 
6.6 Didronel PMO 
Group 7 Obstetrics, Gynaecology 
and Urinary 
7.2 Premarin vag cream 
Orthogynest 
Clotrimazole 
7.3 Loestrin 20 
Mercilon 
Brevinor 
Logynon 
Microgynon 30 
Ma rvelon 
Cilest 
Sphering PC4 
South 
Insulin 
Tolbutamide 
Chlorpr9pramide 
Gliclazide 
Metformin 
Glucose test strip BM-Test 1-44 
BM Accutest 
One Touch 
G2 
Thyroxine 
Carbimazole 
Prednisolone 
Premarin 
Prempak-C 
Climagest 
Kliofem 
Norethisterone 
Danazol 
Premarin vag cream 
Clotrimazole 
Femodene (Vncl ED) 
Minulet 
Logynon (ind ED) 
Microgynon 30 
Marvelon 
Cilest 
Primary Care Drug Formulary 
Comparison of North and South Bedfordsire 
North 
Noriday 
riamisla" 
Dgpo-Provera 
Mirena 
17.4 Oxybutynin 
Group 9 Nutrition & Blood 
1 
19.1 Ferrous sulphate 
Ferrous fumarate 
Pre gada 
Hydroxycobalamin 
Folic Acid 
9.2 Sando-K 
Dioralyte 
9.4 Enteral nutrition eg: 
WT-Sqy 
9.6 Vit 8 tabs, Compound 
Calcichew D3 forte 
Group 10 Musculoskeletal 
10.1 lbuprofen 
Diclofenac 
Indomethacin 
Naproxen 
Mefenamic Acid 
Prednisolone 
Dg, po-Medrone 
Sulphasalazine 
Allopurinol 
10.2 Baclofen 
Quinine Sis 
10.3 Intralgin 
South 
Noriday 
Oxybutynin 
PrA7, nain 
Mefenamic Acid 
Ferrous Sulphate 
Hydroxycobalamin 
Folic Acid 
Dioralyte 
Infasov 
lbuprofen 
Diclofenac 
Indomethacin 
Naproxen 
KetQprofen 
Prednisolone 
Allopurinol 
Intralgin 
Ensure 
Enrich 
Fresubin 
Glutafin 
Hycal 
Primary Care Drug Formulary 
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North South 
Groupll Eye 
11.3 Chloramphenicol 
Fusidic Acid 
Ar-ir-Invir 
Chloramphenicol 
Gentamicin 
11.4 Otrivine-Antistin 
Sodium cromoglycate 
11.6 Pilocarpine 
Timolol 
Dorzolamide 
11 
.7 Amethocaine 
11.8 Hypromellose 
Liquid para n 
Fluorscein 
Group 12 Ear, Nose & Oropharynx 
12.1 Betnesol 
Gendsone HC 
Sofradex 
Olive oil 
12.2 Beclomethasone aq spray 
gphedrine 
Nasg. v 
12.3 Corlan 
Adcortvi in Orabase 
Nystatin 
Group 13 Skin 
13.2 Aqueous Cream 
Emulsifying Ointment 
Paraffin w soft SP 
Unguentum Merck 
Suclocrem 
Oilaturn Emollient 
Diprobath 
Sodium Cromoglycate 
Pilocarpine 
Timolol 
Levobunolol 
Hypromellose 
Gentamicin ear drqps 
Otos-porin 
Tri-Adco! Vi Otic 
Beclomethasone aq spray 
Saline nasal drop 
Aqueous Cream 
Emulsifying Ointment 
E45 
Unguentum Merck 
)ýrpbase pi 
Sudocrem 
Oilatum Emollient 
Balneum 
Emulsiderm 
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North 
13.3 Calamine Lotion 
Eurax 
South 
Calamine Lotion 
13.4 Hydrocortisone 
Alphaderm 
Eumovate 
Betnovate 
Dermovate 
Daktacort 
Canesten HC 
Fuddin 14 
Icill-4hat 
Betamethasone scalp appl 
13.5 Alphosyl 
Alphosyl HC 
Dithranol 
Calciptriol 
Hydrocortisone 
Eumovate 
Betnovate 
Dermovate 
Daktacort 
Timodine 
and Betnovate-RD 
Betamethasone scalp appl 
Polytar Emollient 
Alphosyl 
Alphosyl HC 
Dithranol 
Calcipotriol 
13.6 Panoxyl 
Ouinoderm 
Senzamy; Lin 
Panoxyl 
Tretinoin 
gWhromyqiLn TQpical soln 
13.7 Salicylic Acid Colloidion 
Salactac 
13.9 Capasal 
Polytar Liquid 
Nizoral 
Capasal 
Polytar Liquid 
13.1 OFusidic Acid 
Clotrimazole 
Miconazole 
Terbinaftne 
Aciclovir 
Benzvlbenzoate 
Malathion 
Carbg! yl 
Permethrin 
Magqgqh! ýýýýý 
13.11 Normasol 
Ste od 
Group 15 Anaesthesia 
15.2 kjygef; ý 
Fusidic Acid 
Miconazole 
Aciclovir 
Lindane 
Malathio 
Phenoth, 
Permeth 
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Notes: 84% of the drugs taken by patients on admission to hospital were in 
the formulary 
Sample: 449 drugs 
Duration: Admission date only 
Outcome: Whether drug in formulary or not. 
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